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The use of bioceramics, either alone or with other biomaterials has grown in 
its various biomedical applications over the past 40 years. In the fields of 
orthopaedics and dental surgery bioceramics have been extensively used as 
biomaterials in prosthetic implants as well as bone graft substitutes. Recently, 
the role of bioceramics has been featured in the field of regenerative medicine, 
specifically in the niche of bone tissue engineering. Within this domain, 
apatite based biomaterials can serve as substrates and scaffolds for bone 
regeneration. One of the strategies proposed is the incorporation of in-vitro 
cultured cells which are seeded on the scaffolds to create a more functional 
tissue. However, the conventional method of culturing sufficient cells on the 
scaffold can be inefficient and impractical. Use of microcarriers can overcome 
these issues, but their applicability in bone tissue engineering has not been 
considered.  
The purpose of this report is to describe and evaluate the development of a 
novel apatite based microcarrier. These microcarriers had been fabricated 
using a unique drip casting method. In this method, 0.03 g/ml alginate 
solutioni was mixed with 40 wt.% apatite, and the resultant solution was 
extruded drop-wise through a drop-on-demand device into a 0.5M caclcium 
chloride cross-linking solution. The apatite-alginate beads were then washed, 
dried and subjected to a multi-stage sintering profile to 1150°C, to obtain the 
apatite microcarriers. These microcarriers featured a substantially spherical 
macromorphology of 200 – 300 µm, with a rough surface morphology and 
open porous structure. Chemical characterisation confirmed a phase-pure 
iii!
!
apatite composition without impurities. An in-vitro biological study was also 
conducted to evaluate the microcarriers’ cytocompatibility as well as 
osteogenic potency.  Results demonstrated that the microcarriers were a highly 
viable platform for in-vitro cell expansion, in which proliferation and viability 
were significantly higher when compared with Cytodex® 3. Expressions of 
alkaline phosphatase (ALP), type I collagen (COL1) and osteocalcin (OC) 
were significantly higher over monolayer tissue culture plate controls. A 
preliminary in-vivo study was also conducted on a mouse model to assess 
ectopic bone formation. Over a two-month period, immature bone formation 
was observed, with indications of active bone remodelling.  
In conclusion, these findings would suggest that the apatite microcarriers 
possessed excellent biocompatibility for bone implant applications, and when 
seeded with stem cells, produced osteo-regenerative properties. Ultimately, 
this report aims to evaluate the apatite microcarriers as a viable biomaterial for 
bone tissue engineering, intended as a single-step cell expansion and in-situ 
osteogenic differentiation platform to be implemented as a non-invasive, 
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1.1 Background   
Bone is the a load bearing structure of all vertebrates. It is a composite 
material comprising of mineral and organic phases organised in a complex 
hierarchical structure, starting from the nanoscale up, and functions to serve 
vital mechanical, anabolic and metabolic roles. Bone defects, injuries and 
degeneration can occur either through trauma or disease, or a combination of 
both. These conditions are frequently encountered in clinical practice and 
while conventional methods exist to treat these conditions, complete bone 
regeneration cannot be consistently assured, which can lead to complications 
such as bone non-union and development of post-traumatic osteoarthritis. 
Moreover, bone-related injuries and diseases may be chronic in nature, which 
can certainly cause a considerable strain on healthcare resources due to the 
long-term care required for treatment and rehabilitation. Furthermore, as the 
population in Singapore (or even worldwide) continues to age, the prevalence 
of osteoporosis among the elderly would make them more susceptible to bone 
fractures.  
Currently, the use of bone grafts, obtained from either autogenic or allogeneic 
sources is the preferred strategy for healing of bone defects. Bone grafting 
remains a major need in the global world, which can amount to a demand of 
more than $2.5 billion a year[1]. In the United States alone, approximately 
half of the 3 million musculoskeletal procedures performed annually require 




bone grafting with either an autograft or allograft[2]. Around the world, bone 
grafting involving autografts and allografts account for nearly 2.2 million 
orthopaedic procedures performed annually[3]. While the use of autografts is 
considered as the gold standard for bone defect repairs, this is severely limited 
by donor-site morbidity and availability[1, 4, 5]. In the case of allogeneic 
grafts, challenges imposed include host compatibility, as well as risks of 
disease transmission[5]. As a result, research and development of viable, 
biocompatible, effective and efficacious bone graft substitutes continue to be 
an area of intense interest.  
Several synthetic scaffolds and bone filler biomaterials have been developed 
to serve as substitutes for bone grafts, but these products vary in success. Bone 
graft substitutes featuring macrometer-sized scaffolds such as 
polycaprolactone (PCL) or collagen-based materials are currently available, 
but these scaffolds may not possess the appropriate mechanical properties of 
high compressive moduli and high fracture toughness. While the surfaces of 
these materials can be functionalised with various biomolecules, incorporating 
the correct microstructural properties (pore size, porosity, roughness, 
hydrophobicity, etc.) remain highly complex and can be expensive and time-
consuming. Furthermore, these scaffolds may not conform well to the defect 
site and offer limited flexibility in surgical manipulation, which poses a 
problem in irregularly shaped defects. Bone filler materials that feature 
ceramic granules such as coralline hydroxyapatite, calcium phosphate or 
bioglass have been developed to serve as a less invasive flexible solution for 
filling bone defects. Nevertheless, synthetic bone filler materials currently 




available lack deliberate design of morphology and surface characteristics, 
which fully replicates the microenvironment of the natural bone. These 
solutions remain inferior to their autogenic counterparts and do not sufficiently 
improve healing rates and ensure long-term success.  
It would be ideal if bone fractures can be repaired and healed, where 
functionality of the bone tissues can be restored in a safe, consistent and rapid 
manner by an off-the-shelf product that is cost-effective and easily 
implemented by the orthopaedic surgeon. The concept of using stem cells 
accomplishes this need, regenerating damaged bone tissues, while stimulating 
the body’s own repair mechanisms to assist with the healing process. Stem 
cells have garnered much attention in this regard since they have the ability to 
differentiate while maintaining self-renewal. There are already extensive 
clinical trials being conducted to proof its use, and the potential is highly 
promising. However, one major obstacle in translating this technology from 
bench to bedside is the sheer number of hfMSCs required for successful 
transplantation. A dose of 3 - 5 x 107 cells/patient is needed to treat patients 
with advanced multiple sclerosis [6]whilst 5.7 - 7.5 x 108 cells/kg is required 
for the treatment of osteogenesis imperfecta [7]. The conventional technique 
to achieve such cell numbers involves the expansion of cells on monolayer 
tissue culture flasks. Given that a standard T175 flask is able to yield only 3.5 
- 5 x 106 MSCs at confluence, considerable resources have to be spent on cell 
medium, flasks and incubators, making such a method neither efficient nor 
economically feasible. Furthermore, these cells have to undergo repeated 
passaging which is considered to be labour intensive and time consuming, but 




more importantly, diminishes the capacity for MSCs to retain their stemness. 
The repeated destruction of extra-cellular matrix (ECM) through multiple 
trypsinisation is also likely to decrease intra-cellular signalling responsible for 
cell viability, proliferation and differentiation[8].  To overcome this, the use of 
microbeads has been proposed. This involves the use of micrometre-sized 
spherical particles where cells are seeded upon, and allowed to proliferate 
under gentle dynamic flow conditions. Microbeads have been developed for 
such applications and cell yield up to 108 cells/ml can be achieved [9]. 
However, these microbeads are either polymer or glass based materials, 
making them unsuitable as long-term bone graft substitutes. 
1.2 Objectives  
In order to overcome the above mentioned challenges, development of a tissue 
engineered bone graft substitute, which aims to deliver a single-step, non-
invasive, injectable strategy, which incorporates the properties of 
osteoinduction, osteoconduction and enhances osteogenicity is proposed. This 
can be accomplished through the use of phase-pure porous apatite 
microcarriers, which possess the appropriate physicochemical and 
microstructural properties that enable for in-situ proliferation, differentiation 
and in-vivo phenotypic maintenance of MSCs. 
The specific objectives can be summarised as such: 
• Develop suitable novel apatite-based porous microcarriers as cell 
carriers. 




• Establish the apatite-based porous microcarriers as an efficient tool for 
obtaining high yield mesenchymal stem cells (MSCs) isolation and 
expansion in-vitro. 
• Establish the apatite-based porous microcarriers as an efficient 
platform for driving directed differentiation of MSCs into osteogenesis 
in-vitro. 
• Evaluate the efficacy of the MSC-loaded apatite-based porous 
microcarriers to generate ectopic bone formation in-vivo. 
1.3 Scope 
Chapter 1 establishes the background and motivation of this dissertation, 
which demonstrates the need for bone tissue engineering, and the development 
of novel biomaterials. It is proposed that the use of phase-pure porous apatite 
microcarriers will be a superior alternative over conventional monolayer 
culture techniques. This is hypothesised to enhance bone regeneration when 
used as a bone graft substitute. Chapter 2 summarises the relevant literature 
regarding bone, bone tissue engineering and bioceramics, in which key design 
considerations are highlighted in the development of a bone tissue engineered 
biomaterial. Chapter 3 presents a detailed study on the fabrication of the 
apatite microcarriers, which includes the characterisation of its 
physicochemical properties, as well as optimisation of the various parameters 
for the fabrication of an apatite microcarrier that is relevant for its intended 
application. Chapter 4 details the evaluation of the apatite microcarriers in-
vitro, to assess its cytocompatibility and effects on the osteogenic potency on 
mesenchymal stem cells, so as it establish its efficacy as a microcarrier for in-




vitro cell culture. Chapter 5 further evaluates the apatite microcarriers as 
implantable bone graft substitutes, through an in-vivo study on ectopic bone 
formation in a mouse model. Properties of biocompatibility, osteogenicity and 
neo-vascularisation are investigated. Chapter 6 gives an overall conclusion of 
the present work. Chapter 7 provides an outlook of the possible future work 
and development of the apatite microcarriers so as to increase its relevance 














Literature Review  
2.1 Bone biology 
In order to develop engineering considerations for the bone tissue engineered 
construct, it is necessary to understand the biology of bone. The bone is the 
major load-bearing organ of all vertebrates. In addition to providing 
mechanical stability, it is vital in the process of haematopoiesis, and 
functioning as the main repository for adult mesenchymal stem cells as well as 
hematopoietic stem cells. Furthermore, it plays several metabolic functions 
including mineral storage, growth factor storage, and maintaining acid-base 
balance. Bone has also been implicated as fulfilling the endocrine role of 
maintaining glucose and phosphate homeostasis by producing hormones such 
as FGF23 and osteocalcin which influence phosphate disposal and glucose 
utilisation respectively[10]. 
2.1.1 Physicochemical characteristics of bone  
 
Figure 2.1. Hierarchical nature of bone[11]. 




Chemically, bone is composed of an organic phase consisting of mainly 
collagen (35% dry weight) and a mineral phase of carbonated apatite (65% dry 
weight). These phases are organised in a highly hierarchical structure (Figure 
2.1). At the macroscale level, bone can be described an organ consisting of 
two kinds of osseous tissue: cortical bone and trabecular bone. Cortical bone 
covers the outer surface of the bone and is a dense and compact tissue, which 
sustains major loading forces.  It is thickest at the middle of the shaft and 
becomes thinner at both ends of the bone. At the proximal and distal ends of 
the bone, where cortical bone is the thinnest, bone transitions into a less dense 
and more porous structure, or trabecular bone. This is to facilitate load transfer 
during articulation[12]. Trabecular bone has an average density of 0.2 g/cm3 
and porosity as high as 90%, with 1 mm spacing between the trabecular 
columns. In comparison, cortical bone is much denser at 1.80 g/cm3, with a 
porosity of 3-12% with no visible macropores. Microscopically, both cortical 
and trabecular bone are made up of Haversian systems (osteons) which are 
layers of compact bone stacked in concentric layers around a Haversian canal 
which contains the bone’s blood vessels and nerves. These concentric layers, 
or lamellae, have a nanoarchitechture consisting of bundles of collagen fibres 
interspaced with apatite crystals[11]. These lamellae are stacked in an 
alternating fibre orientation at 45° to the vertical axis. Collectively, the nano-, 
micro-, and macro-scale architecture of bone is responsible for its unique 
rigidity, viscoelasticity and toughness. In addition to contributing to its 
mechanical properties, the microstructure of bone forms a unique 
microenvironment for the bone cells. The four main mature cells that 




contribute to synthesis and remodelling of the bone matrix are osteoblasts, 
osteoclasts, osteocytes and periosteal cells. Stem cells such as mesenchymal 
stem cells and hematopoietic stem cells are found in the bone marrow situated 
within the central intramedullary cavity of the bone shaft and between the 
trabecular spaces. These cells are responsible for the dynamic nature of the 
bone; constantly remodelling itself in response to external loading conditions, 
a feature which has to be taken into account when designing a tissue 
engineered construct and will be covered in Section 2.2.2. From an 
engineering viewpoint, the bone can be regarded as a polymer-ceramic 
composite in which the lamellar polymer fibre structure is interspaced with a 
ceramic.  Each parameter such as bone composition (porosity, mineralisation) 
as well as structural organisation (nano, microarchitecture, fibre orientation) 
has profound effects on the overall mechanical property of the bone.  
 
Figure 2.2. A schematic diagram illustrating the assembly of collagen 
fibrils and fibres and bone mineral crystals. The well known 67 nm periodic 
pattern results from the presence of adjacent hole (40 nm) and overlap (27 nm) 
regions of the assembled molecules[11]. 




Type I collagen, which is the most abundant form of collagen in the bone, is a 
fibrillar heterotrimer collagen consisting of two identical polypeptide α1 
chains and one α2 chain arranged in a right-handed triple-helical structure, 
stabilised by covalent crosslinks. Each collagen molecule is 300 nm in length 
and approximately 1 nm thick (Figure 2.2), and several molecules of collagen 
are stacked to form fibrils of 50 – 500 nm thick. The fibrils then stack together 
again to form bundles, which constitute to the collagen fibre of 3 – 7 µm thick. 
Collagen has an elastic modulus of 1 – 2 GPa and ultimate tensile strength of 
50 – 1,000 MPa. This contrasts with hydroxyapatite, which exists as nano 
crystals within the fibrillar structure of collagen. It has an elastic modulus of 
approximately 130 GPa, and an ultimate tensile strength of 100 MPa. The 
combination of these two materials with dissimilar properties in a composite 
structure allows for bone to have a wide range of mechanical properties that is 
tuned specifically to the intended function, and responds preferentially to the 
type of loading applied, and is able to withstand high impact forces (Table 2.1). 
Table 2.1  Mechanical properties of cortical bone and trabecular 
bone[13]. 
Property Cortical bone Trabecular bone 
Compressive strength (MPa) 100 – 230  2 – 12  
Tensile strength (MPa) 50 – 150 10 – 20  
Strain to failure (%) 1 – 3  5 – 7  
Fracture toughness (MPa) 2 – 12 -  
Elastic modulus (GPa) 7 – 30 0.5 – 0.05 
Due to the hierarchical nature of bone, it is therefore necessary to highlight the 
differences in mechanical properties across the different levels of organisation 




(Table 2.2). From this it is evident that changes to the microstructure of bone 
will result in differing macrostructural properties although the composition of 
bone may be the same. 
Table 2.2. Elastic modulus of bone according to different levels of 
organisation[14]. 
Level of organisation Elastic modulus (MPa) 
Macrostructural 14 – 20  
Microstructural 5.4 
Submicrostructural 22 
2.1.2 Fracture healing mechanism 
Understanding the pathophysiological process of bone healing would enable 
considerations to be made for the in-vivo response of the bone tissue 
engineered construct. For biocompatibility of the biomaterial to be ensured, a 
systematic approach to design the engineered construct is required such that 
the biomaterial enables a seamless integration throughout the healing process; 
from the initial inflammatory response, to repair and remodelling phases, such 
that the engineered construct achieves it intended effect by ensuring 
appropriate host-tissue response, while avoiding undesirable consequences 
such as fibrotic encapsulation, osteolysis or systemic inflammation.  
 




Figure 2.3. The fracture healing process. The fracture hematoma (A) is 
transformed into granulation tissue first, followed by migration and 
differentiation of MSCs and fibroblasts into osteoblasts and chondrocytes 
respectively (B). Mineralisation of the callus occurs, forming woven bone (C). 
Restoration of the cylindrical shape occurs through remodelling of the bony 
callus to lamellar bone (D)[15] 
Bone healing is governed by the biomechanics of the fracture site as well as 
availability of blood to the healing site. Healing is characterised by three 
phases: inflammatory, repair and remodelling (Figure 2.3). In each phase, an 
orchestrated sequence of events overlaps one another (Figure 2.4). Thus, 
facilitation and enhancement of these events will lead to faster recovery times, 
as well as decreased incidence in non-union.  
Following injury and/or trauma, the rupture of blood vessels causes blood to 
fill the area, and damage to tissues and cells results in a release of 
proinflammatory factors, which initiate the inflammatory cascade. Within the 
facture gap, fibrinogen from blood plasma is converted to fibrin, which results 
in an insoluble mass of blood clot known as hematoma which contains the 
damaged tissue, inflammatory cells, as well as proinflammatory and anti-
inflammatory cytokines, which serve the signal the recruitment of more 
inflammatory cells. Neutrophils, mainly polymorphonuclear neutrophils 
(PMNs) are the first cells to reach the site and these short-lived cells serve to 
recruit macrophages, which act to clear the injury site of debris and any 
foreign bodies. Presence of PMNs impede the progression of the healing 
phases into the bone repair phase. Persistence of PMNs can be an indication of 
delayed fracture healing. As such, biomaterials that modulate the response of 
PMNs and which prevent overactivity of PMNs can be beneficial towards 




enhanced bone healing rates. Macrophages, on the other hand, have been 
identified as essential towards MSC recruitment and osteogenesis. 
Lymphocyte migration to the healing site occurs towards the end of the 
inflammatory phase, and they function to regulate the immune response at the 
site. The proinflammatory cytokines, IL-1, IL-6, TNF, RANK ligand, as well 
as the TGF-β superfamily that includes BMP-2, BMP-4, BMP-5 and BMP-6, 
are released during the initial inflammatory phase and are identified to be key 
osteoinductive factors, essential towards the subsequent phase of bone repair 
through the signalling MSC migration, proliferation and differentiation. In 
addition, growth factors such as angiopoetin-1 (ANG-1) and vascular 
endothelial growth factor (VEGF) released in response to the hypoxic 
conditions created by the hematoma function to stimulate blood vessel 
formation through angiogenesis by signalling the endothelial cells from the 
surrounding intact periosteal vessels to grow in the direction of the hematoma. 
Revascularisation of the healing site following fracture has been established as 
an essential step in healing; functioning to bring essential nutrients and cells to 
the healing site, while removing debris and waste. 
The repair phase is characterised by the recruitment of MSCs to the healing 
site, differentiation into osteoblasts, production and mineralisation of 
extracellular matrix (ECM). Depending on the biomechanics of the healing 
site, repair proceeds via two mechanisms: intramembranous ossification and 
endochondral ossification. Where there is little perturbation to the healing site, 
the predominant mechanism is intramembranous ossification. If the fracture 
surfaces are in contact with one another and in compression, Haversian 




systems develop across the gaps and mature bone is laid over these systems 
via the formation of a basic multicellular units (BMUs) consisting of both 
osteoclasts and osteoblasts which function to resorb bone and form bone 
respectively[16]. Where a gap between the fractures is present, woven 
(immature) bone is first laid down and vascularised from the periosteum and 
medulla, before being bridged by osteon formation. This process is a relatively 
long one, where complete repair can take up to 3 years[17]. Endochondral 
ossification is the main mechanism in healing sites where stability is low and 
interframentary movement is high. In this process, high movement of the 
hematoma stimulates the development of a granulation tissue consisting of 
leukocytes, macrophages, and fibroblasts. A fibrous soft fibrous callus 
formation grows in the direction of the fracture gap. This is driven by 
chondrocytes derived from fibroblasts which are exposed to the hypoxic 
environment in the hematoma[18]. Once the fracture gap is filled with soft 
callus, calcification of the callus occurs as the chondrocytes become 
hypertrophic and undergo apoptosis. At this stage, interfragmentary movement 
is markedly decreased, which paves the way for blood vessel invasion and 
migration of MSCs and monocytes to the callus. The monocytes form multi-
nuclear units similar to osteoclasts, which resorb the cartilage, while MSCs 
undergo osteogenesis to differentiate into osteoblasts, which replace the 
resorbed cartilage with woven bone. The subsequent bony bridging further 
increases stability to the healing site, which in turn promotes intramembranous 
ossification, which supplements the repair phase. Complete mineralisation of 




the soft callus marks the end of the repair phase. At the same time as repair 
activity diminishes, the remodelling phase is initiated (Figure 2.4). 
This is the phase whereby resorption of the periosteal callus occurs by 
osteoclast activity at the surface of the bone. At the same time, woven bone is 
converted gradually to lamellar bone such that it is laid in the direction of 
applied stress. Bone remodelling proceeds in five distinct phases: 
1. Resting state: The surface of the bone is lined with inactive cells. 
Former osteoblasts are trapped as osteocytes within the mineralized matrix.  
2. Activation: Hormonal or physical stimuli signal mononuclear 
monocytes and macrophages to migrate to the remodelling site and 
differentiate into osteoclasts. Sites with microfractures or microdamage may 
exhibit a certain predisposition for remodelling.  





Figure 2.4. Sequence of events following fracture in a rat model. a) 
Fracture healing can be divided into three overlapping phases: inflammation, 
repair and remodelling. b) IFM varies over the course of fracture healing. c) 
Blood flow is represented as percentage change from pre-fracture levels. d) 
Tissue composition varies throughout fracture repair. Abbreviations: IFM, 
interfragmentary movement[19]. 
 




3. Resorption: Osteoclasts begin to remove the organic and mineral 
components of bone and form a cavity of characteristic shape and dimensions 
called a Howship's lacuna in trabecular bone and a cutting cone in cortical 
bone. When the cavity reaches a depth of about 60 µm from the surface in 
trabecular bone and about 100 µm in cortical bone, resorption at that location 
ceases.  
4. Reversal: Osteoclasts die and mononuclear macrophage-like cells 
smooth the resorbed surface by depositing a cement-like substance that will 
bind new bone to old. Pre-osteoblasts begin to appear. This phase is 
characterized by factors that stimulate osteoblast precursors to proliferate, 
including IGF-2 and TGF-β.  
5. Formation: Differentiated osteoblasts fill in the resorption cavity and 
begin forming new osteon in a two-stage process. First, they deposit osteoid 
(mostly collagen type I). The rate of matrix apposition is initially very rapid 
and the osteoblasts are columnar and densely packed. Mineralisation of the 
osteoid commences when the cavity has been filled to 20 µm. With the onset 
of mineral apposition, the rate of mineralization exceeds the rate of matrix 
apposition and continues, with a substantially lower rate, even after the 
termination of matrix synthesis, until the bone surface returns to its original 
resting state.  
The remodelling process is long term and occurs until the bone approaches its 
original geometry, strength and stiffness, optimised to the external mechanical 




stimuli[20]. During this phase, vascularisation within the callus is also reduced 
to match that of the original site[21]. 
In summary, the bone healing process is defined by three phases: 
inflammation, repair and remodelling. Non-union and delayed healing of bone 
is due to a failure in any one of the three phases. A biomaterial or bone tissue 
engineered construct which has properties which can initiate, facilitate and 
modulate through the different healing phases will have immense benefits of 
stimulating, enhancing and maintaining the body’s own regenerative capacity 
in bridging the bone defects. These materials can achieve such an effect by 
employing different strategies. The ‘diamond concept’ has been proposed by 
Giannoudis et al., in which growth factors, osteoconductive scaffolds, MSCs 
and mechanical environment are the four main factors that should be 
considered in the treatment of fractures[22]. Indeed, the use of bone 
morphogenetic proteins (BMP-2 and BMP-7), released by cells during the 
inflammatory phase, have been extensively studied to deliver an 
osteoinductive effect and are in clinical use currently[23-28], and these have 
been incorporated into scaffolds for the treatment of critical-sized defects[29-
31]. Other inflammatory cytokines such as VEGF and PDGF have also been 
studied to achieve revascularisation and angiogenesis in tissue engineered 
scaffolds[32-34]. In consideration of osteoconductivity, bioceramics play a 
fundamental role in the development of bone tissue engineered scaffolds 
because of their excellent biocompatibility with bone tissue, as well as their 
physicochemical properties which allow scaffold to achieve mechanical 
properties close to natural bone[35]. Various parameters that affect the micro- 




and macro-structure of these materials can be designed using current 
engineering techniques, and these will be crucial towards ensuring an 
appropriate microenvironment for cell-ingrowth as well as blood vessel 
formation.  MSCs, in addition to their ability to undergo osteogenesis, are key 
to the entire bone healing process, functioning to modulate the transition 
between phases, and synthesising new bone. As such, various biochemical and 
surface topological cues have to be arranged in a spatio-temporal manner 
which mimics the in-vivo microenvironment of these cells for the most 
optimal results to be achieved[36]. Finally, the biomaterial or bone tissue 
engineered construct has to allow for appropriate transmission of mechanical 
stimulation, as the concept of mechanotransduction is crucial towards the 
understanding of bone remodelling. 
2.1.3 Stress shielding and bone mechanotransduction 
In the early 20th century, metallic orthopaedic implants used in total hip 
arthoplasty faced problems of stress shielding, whereby reduction in bone 
mass is observed around the area where the implant is placed. This is caused 
by the mismatch in stiffness of the implant material and the surrounding bone, 
resulting in removal of stresses experienced by the bone. This led to the 
discovery of Wolff’s law, which states that the bone will remodel itself in 
accordance to the experienced stress field; increased loading results in denser 
bone in the direction of the applied stress, while greater bone resorption occurs 
in areas experiencing less loading. This underscores the importance of 
mechanical stimulation in the development of orthopaedic implants such that 




consideration of the material’s elastic modulus and stress field influences at 
the implant site forms an important facet in material selection.  
Wolff’s law is implicated in the bone remodelling process, which occurs 
throughout an individual’s lifetime. This process involves the conversion of 
mechanical stimuli into biochemical signals in a process known as 
mechanotransduction. Osteocytes are the main cells that sense changes in the 
applied mechanical stresses.  
The matrix around osteocytes and processes is not calcified and they 
interconnect with one another to establish a three-dimensional network. This 
network extends towards the periosteum, making contact with the bone lining 
cells. Such a network creates a highly sensitive mechano-sensing tissue that 
confers dynamic properties to bone[37]. Its close proximity to the MSCs and 
the periosteum allows contact with osteoblasts and osteoclasts, while water 
and small molecules can penetrate their network of lacunae (space occupied 
by the body of the osteocyte) and canaliculi (channels that allow the processes 
of osteocytes to come in contact).  
The microenvironment that is created from this network is instrumental in 
bone mechanotransduction. During increased mechanical strain, excessive 
stimulation of osteocytes increases the release of osteoblastic factors and 
induces bone growth. The transfer of signals via the gap junctions of the 
lacuno-canalicular network is believed to induce recruitment of osteoblasts. As 
extra bone is produced, the basal mechanical loads in bone are restored and 
bone growth ceases. Conversely, during mechanical unloading, as in the case 




of stress shielding, decrease in osteocyte stimulation leads to osteocyte 
apoptosis, which in turn signals for an increase in osteoclastic activity. The 
resultant increase in bone resorption occurs and bone density decreases until 
the new norm in mechanical loading is achieved[38]. In addition to 
mechanical strain, it has been noted that fluid shear stresses in the lacuno-
canalicular network manifests from external loading conditions also play a 
role in underlying the mechanism of Wolff’s law. Reich et al. has reported that 
osteoblasts express increased amounts of Expressions of cyclic adenosine 
monophosphate (cAMP); a known mediator of bone formation, by osteoblasts 
was shown to increase when cultured at shear rates as low as 10 s-1. Increase in 
viscosity, which results in increased fluid shear stress, corresponded to a 
proportional increase in cAMP[39]. Nitric oxide (NO) and prostaglandins E2 
and I2 (PGE2 and PGI2) have also been shown to be expressed in greater 
amounts by both osteoblasts and osteocytes when subjected to fluid shear 
stress[40-42]. NO is a free radical known to promote vascularisation and 
angiogenesis, inhibit osteoclastic activity and stimulate osteoblastic 
proliferation, while PGE2 and PGI2 are involved with bone 
mechanotransduction as well as bone formation. 
From this, it is clear that the immediate microenvironment around the cell 
plays an important role in which the cell senses changes. This is achieved by 
cell-surface receptors (integrins) that mediate both cell attachment and serve 
as link between the matrix and the cytoskeleton. In such a mechanism, 
physical stimulus applied to the bone matrix gets transmitted to the cells via 
integrins, which then induce changes to the organization of the cytoskeleton, 




which leads to gene upregulation or downregulation. Similarly, biomaterials 
not only serve to create a scaffold for tissue structure, but also transmit 
information to the attached cells. Specifically, the mechanical strain causes a 
change in clustering of integrins and their associated intracellular protein 
configuration leads to cytoskeleton polymerisation/ depolymerisation and 
reorganisation, thus changing the morphological structure of the cell[43]. This 
has been demonstrated by Rhee et al., in which differences to matrix rigidity 
or exogenous tension determines rate of fibroblast migration through strength 
of matrix-ligand binding and density[44].  
2.1.4 Cellular Response 
The degree to which attached osteoblasts respond to physical simulation can 
be influenced by the strength of adhesion to the biomaterial. The strength of 
adhesion is in turn governed by the biomaterial’s surface morphology and 
chemistry[45]. Depending on the microenvironment and material surface 
characteristics, cells can respond to the tension created through rearrangement 
of their cytoskeletal network[46].  Cytoskeletal network organisation has been 
implicated in osteoblast proliferation and differentiation, whereby MSCs 
undergo distinct cytoskeletal changes during osteogenic differentiation 
(fibroblastic to round, spindle-shape). Clearly, cell-matrix interactions play a 
fundamental role during osteogenesis. Osteoblasts adhere preferentially to 
matrix components through focal adhesion contacts, and this adhesion is 
primarily mediated by integrins and cadherin which form connections with 
both the cytoskeleton and ECM[47]. Indeed, FAK signalling through integrin 
engagement has been identified as playing a critical role in regulating ECM-




induced osteogenic differentiation among MSCs[48]. As such, engineering a 
biomaterial that has physicochemical cues that induce integrin binding and 
clustering in a spatially specific manner can be a potential way to guide bone 
regeneration. 
2.2 Bone Tissue Engineering 
Traditionally, orthopaedic surgeries for the treatment of bone diseases, repair 
of bone defects due to trauma or tumour removal involved the use of 
autografts, which is often considered as the ‘gold standard’ of treatment. 
However, the limited availability of bone tissue and donor site morbidity 
represent major limitations with autografts[49, 50]. The use of allografts and 
xenografts circumvent this problem, but they present significant risks of 
adverse immune reaction, tissue rejection as well as viral or bacterial 
infection[51]. Furthermore, there were persistent issues of insufficient 
revascularisation and remodelling, which are speculated to contribute to 25% 
of allograft failures and 30 – 60% of post-operative complications. 
In light of this, there have been extensive research and development into 
naturally derived and synthetic bone graft substitutes over the last 30 years. 
This forms the basis for development of a subset of biomaterials, whereby 
specific set of considerations were established in order to achieve a 
biomaterial that would ensure adequate biocompatibility with the surrounding 
bone tissue, while fulfilling its intended goal of restoring function to the 
damaged or replaced tissue.  




Initially, metallic prostheses were chosen as implant biomaterials, where 
primary concerns were focused on withstanding mechanical loads and 
ensuring structural integrity. However, it soon became evident that metallic 
implants faced long-term issues of insufficient integration with the host tissue, 
resulting in complications such as aseptic loosening, implant migration, and 
osteolysis. In addition, the tribology of these materials when used in 
articulating surfaces also resulted in unintended host response. These metals 
while in bulk, insoluble forms were harmless, elicited strong local and 
systemic immunological response when exposed to wear and tear due to the 
release of metal ions and debris into the system. This prompted thorough 
deliberations into the actual definition of ‘biocompatibility’ where it became 
widely accepted that the biomaterial should elicit a favourable host-tissue 
response, while preventing any adverse immunologic effects.  
Better appreciation of the bone biology and fracture healing process (See 
Section 2.1.2) made the issue of biocompatibility even more relevant in the 
paradigm of host-implant integration. The ‘diamond concept’ of an ideal bone 
substitute material was introduced, whereby properties of osteoinduction, 
osteogenesis and osteoconduction should be incorporated into a three-
dimensional structure that mimics the in-vivo microenvironment and contains 
appropriate mechanical properties that sustains loading, promotes 
revascularisation and allows for mechanical and fluidic stimulation.  
From this, the concept of bone tissue engineering emerged. Fundamentally, 
the development of functional, biological solutions to repair or replace 




damaged tissues and organs is the goal of tissue engineering.  This involves 
the interplay between cells, scaffolds and biomolecules that would generate a 
favourable response when implanted into the patients, thus restoring functions 
lost or impaired due to injuries or disease. This chapter will focus on the key 
design considerations of a tissue engineered construct, which encompasses an 
overview of the types of the various scientific disciplines that are required. 
Particular attention will be devoted to a review on the use of bioceramics, 
which play an indispensible role in majority of bone graft substitutes as well 
as bone tissue engineered constructs. This is because of their unique 
physicochemical properties, which can produce an osteoconductive effect. 
Bioceramics, when used in conjunction with synthetic polymers or other 
naturally derived materials, have the potential to create a truly biomimetic 
biomaterial ideal for bone tissue engineering applications. 
2.2.1 Biocompatibility 
Biocompatibility is the most fundamental requirement that has to be fulfilled 
by all biomaterials. Defined as “the ability of a biomaterial to perform its 
desired function with respect to a medical therapy, without eliciting any 
undesirable local or systemic effects in the recipient or beneficiary of that 
therapy, but generating the most appropriate beneficial cellular or tissue 
response in that specific situation, and optimising the clinically relevant 
performance of that therapy”[52],  it entails a deliberate and meticulous 
method of appreciating the specific physiological environment that the 
biomaterial is being implanted to, the function that it intends to replace or 
restore, and the physio-biological processes that enable seamless acceptance 




into the body. This “living in the problem” paradigm spurred intense research 
and development of key design considerations that demands an 
interdisciplinary approach, which would engineer a biomaterial with 
characteristics that direct host response along its intended path. Broadly, three 
strategies were undertaken to achieve this: bioinert, bioactive and 
bioresorbable. Bioinert biomaterials were developed due to insufficient 
understanding of the host tissue response and are no longer considered as a 
material with good biocompatibility. Bioactive biomaterials represent the next 
generation of biomaterials, able to initiate, promote or maintain a certain host 
tissue response, which is believed to be beneficial towards repairing or 
replacing tissue function. Within the strategy of incorporating bioactivity, 
bioresorbable biomaterials are materials that become resorbed into the body 
either by dissolution or metabolic processes, which are favourable in specific 
cases where complete tissue regeneration and restructuring is expected. These 
materials serve as temporary scaffolds for cell adhesion, guiding tissue 
formation while performing biochemical and biomechanical functions before 
the regenerative process is complete. For example, bioresorbable VICRYL™ 
(polyclactin 910) sutures made of a mixture of 90% glycolide and 10% L-
lactide are used in various applications requiring soft tissue ligation. These 
sutures serve the function of stitching tissues together and is resorbed into the 
body once the incision heals over, reducing the formation of scar tissue[53].  
Within the context of bone tissue engineering, the concept of incorporating 
bioactivity, whether through bioresorbable or long-term implants, can be 
further sub-divided into three properties of action: osteoinduction, 




osteogenicity, and osteoconduction. No single material, apart from autografts, 
has been able to incorporate all three properties of action, and all current bone 
graft substitutes employ a combination of cell, growth factor and material 
based approaches to achieve these properties. A summary of bone graft 
substitutes currently available has been provided in Table 2.3. 
Table 2.3. Summary of bone graft substitutes currently available[54]. 
Class Description Examples Properties of 
action 





Alone or combination with 
other materials 




Natural or recombinant BMP, TGF-β, PDGF, FGF, 
VEGF 
Osteoinductive 
Cell based Cells used to generate new 
bone 
MSCs, ESCs, iPSCs, 












Includes degradable and 
nondegradable polymers 
used alone and in 
combination with other 
materials 
Cortoss, OPLA, Immix Osteoconductive 
Naturally 
derived 
Type I collagen mixed 
with calcium phosphates  
Integra Mozaik, MasterGraft 




(with addition of 
rhBMP-2) 
These three approaches to bone graft substitutes can be further elaborated as 
such: 
1. Cellularised therapies 
These are usually osteoblasts or their derived progenitors. Such cells are 
usually isolated, grown and differentiated down the osteogenic lineage in-vitro 




before being implanted into the healing site. These cells can either be of 
allogeneic or autogenic sources and they contribute directly to the synthesis of 
new bone ECM (i.e. osteogenicity). 
2. Growth factor incorporation 
Growth factors are signalling biomolecules that stimulate cellular migration, 
proliferation, and differentiation. These are obtained either from natural or 
recombinant sources, and when applied in bone tissue engineering applications, 
deliver an osteoinductive effect by attracting MSCs, promoting osteogenic 
differentiation, and bone mineralisation. Examples of these growth factors 
include BMP-2, BMP-7, as well as TGF-β. Other growth factors such as 
fibroblast growth factor (FGF), platelet-derived growth factors (PDGF) and 
vascular endothelial growth factor (VEGF) are also used as these growth 
factors deliver the stimulatory effect of inducing vascularisation and 
angiogenesis[55]. Growth factors are highly potent biomolecules that have to 
be tightly regulated during their release into the host tissue. Use of growth 
factors in orthopaedic therapies is still limited because of their prohibitively 
high costs, and possible side effects or tumorgenesis[56, 57]. 
3. Biomaterials as scaffolds 
Biomaterials underlie the bone tissue engineering approach. They function to 
provide a three-dimensional structure that guides cell migration, proliferation 
and differentiation. They form the base substrate for which cellular therapies 
and growth factors can be incorporated. While some tissue engineering 
applications can feature scaffold free strategies, the need for scaffolds is 




essential in bone graft substitutes, because the construct is required to bridge 
gaps in defects and sustain mechanical loading while the bone healing process 
is underway. The types of biomaterials used as scaffold include metals such as 
cobalt-chromium-molybdenum, stainless steel and titanium, polymers such as 
polycaprolactone (PCL), poly lactic-co-glycolic acid (PLGA), and poly (l-
lactic acid) (PLLA), and ceramics such as zirconia, calcium phosphates and 
bioglass. Another class of biomaterials is derived from natural origins, and 
these include demineralised bone matrix, collagens, chitosan and silk[58]. 
2.2.2 Design considerations: Mechanical properties, degradation 
profile, surface characteristics, porosity and pore size 
Through an in-depth appreciation of the bone biology and the healing process 
(Section 2.1), a general agreement on the design considerations can be 
established. Since the biomaterial is expected to undertake mechanical 
functions, it should have mechanical properties which resemble that of the 
natural bone. Structurally, they should not undergo massive deformation under 
normal loading conditions, but should demonstrate visco-elastic strain 
characteristics to allow for proper mechanotransduction. Figure 2.5 illustrates 
the stiffness to strength relationship of commonly used biomaterials and where 
they stand with respect to tissues in the body.  
While metals and alloys possess high stiffness and strength, they can result in 
issues related to stress-shielding due to the mismatch in stiffness compare to 
the host tissue, and have limited biocompatibility. Polymers may have 
stiffness and strength resembling that of soft tissues and trabecular bone, but 
possess undesirable effects of undergoing permanent deformation with 




sustained loading. Bioceramics, which represent the bulk of currently 
available bone graft substitutes, are favoured because they are highly 
biocompatible with the host tissue, and have high stiffness and compression 
strength. However, they fail easily through brittle facture during tensile 
loading and are difficult to manipulate to form complex shapes. Use of 
bioceramics has been traditionally restricted to granule forms and coatings. 
Increasingly, with the development of new fabrication technology, composites 
featuring combination of both polymers (natural or synthetic) and bioceramics 
are being developed, offering unique opportunities of customising the 
material’s properties to match that of the host tissue.  
 
Figure 2.5. Ashby map illustrating the comparison of Young’s modulus 
(Stiffness) to strength of various biomaterials. Note that stiffness and strength 
of metals and their alloys are generally several orders of magnitude higher 
than that of other materials and biological tissue[59]. 
!




In bone tissue engineering, the degradation and resorption characteristics of 
the biomaterial should be designed to progress in tandem with the healing 
process, sustaining mechanical loads while new tissue grows over. This is to 
maintain a stable microenvironment for cell proliferation and vascularisation 
of the construct. This should be designed with the type of bone that the 
biomaterial intends to replace. In trabecular bone, it should degrade within 6 – 
12 months, while in cortical bone, 6 – 12 months, to allow the remodelling 
phase to proceed. For example, by mixing calcium phosphates of an insoluble 
phase of hydroxyapatite (HA) with a highly soluble phase of amorphous 
tricalcium phosphate (TCP) in the creation of biphasic calcium phosphates 
(BCP) it is possible to tailor the degradation characteristics of the biomaterial 
ranging from weeks to years. Ultimately, the purpose here would be to select 
and develop a biomaterial for the specific bone tissue engineering application. 
As such, biomaterials featuring a composite of different materials that 
complement one another are increasingly favoured over traditional 
biomaterials. 
Upon introduction into the biological environment, proteins and other 
biomolecules from the surrounding serum are adsorbed onto the biomaterial’s 
surface. It is this protein layer that interacts with the cell, rather than the actual 
biomaterial. Specific control of this layer chemically as well as spatially would 
allow for direct manipulation of cellular responses. For instance, the 
bioactivity of certain bioceramics such as calcium phosphates and bioglasses 
can be attributed to the dissolution-reprecipitation mechanism, whereby an ion 
exchange process occurs, resulting in the creation of an apatite layer. This 




layer is key towards enabling proper osteoblast adhesion, spreading and 
phenotypic expression, and is crucial towards ensuring host-tissue 
osteointegration. i.e. Absence of a bioactive apatite layer is a known cause of 
fibrous tissue encapsulation. 
It has been well established that cellular biomechanics function at the 
submicron level. Several biochemical pathways involving cellular 
proliferation, differentiation and regulation are due to the functional changes 
in the immediate micro/nano environment surrounding the cells. If a group of 
integrins are engaged in a particular sequence or arrangement, different 
cellular signalling pathways can be promoted or inhibited. This effect was 
demonstrated in a study involving an array of nano-scale geometries ranging 
from nanogroove, nanopost, and nanopit arrays, to study the effects of cellular 
contact guidance. In the study, it was observed that epithelial cells elongated 
and aligned along the patterns of grooves and ridges with feature dimensions 
as small as 70 nm, whereas cells were mostly rounded on smooth surfaces[60].  
Certainly, such topological cues would present an opportunity for nano-scale 
engineering of a bone scaffold where scaffold constructs comprising of 
nanobioceramic crystals can be made to align to the c-axis of the bone, thus 
allowing for the adhesion of osteoblast cells along this axis, and produce ECM 
which would further enhance strength and integrity of the implanted scaffold.  
Already such a concept has been proposed by Kim et al. where they have 
demonstrated that cellular attachment and proliferation was improved through 
the use of a nanocomposite of HA nanocrystals embedded in a nanofiber 




composed of gelatin[61]. Osteoblast adhesion is dependent on surface 
topology, and it has been shown that nanophase surfaces promoted better 
adhesion than microscale materials[62]. The experiments showed that a 30 and 
46 % increase in osteoblast adhesion on nanophase titania (grain size 32 nm) 
and alumina (grain size 23 nm), respectively when compared to the 
conventional bioceramics[63]. In fact, nanotopology alone may account for 48 
– 51 % of the total osteoblast adhesion as shown in an experiment by Palin et 
al. who showed that poly (lactic-co-glycolic acid) PLGA modelled after 
nanophase titania showed a similar percentage increase in osteoblast adhesion 
as compared with nanophase titania[64]. Moreover, alkaline phosphatase 
(ALP) and ECM calcium content were significantly increased when 
osteoblasts were cultured on nanophase bioceramics, compared with the 
conventional microscale ceramics (Table 2.4)[65].  
Table 2.4. Percent increase in ALP and ECM calcium content for 
osteoblasts cultured on nanoscale compared to microscale bioceramics after 28 
days[65] 










Alumina Conventional      167 
 
Nanophase           24 
36 4 times 
Titania Conventional    4250 
 
Nanophase            39 
22 6 times 
Hydroxyapatite Conventional      179 
 
Nanophase           67 
37 2 times 
Porosity, pore size and pore interconnectivity of the biomaterial is the last set 
of considerations that should be taken into account for the development of 




bone tissue engineered construct, but it is by no means the least important. In 
fact, porosity and pore size are important determinants to osteogenicity of the 
biomaterial, and its long-term performance is directly dependent on this 
material property. Kuboki et al. has demonstrated that presence of pores of 
hydroxyapatite allowed for migration and proliferation of MSCs and 
osteoblast, as well as blood vessel formation. Porosity, or percentage void 
space in a solid, contributed to the availability of the biomaterial’s surface for 
protein adhesion, cellular adhesion and growth. The specific dimensions and 
interconnectivity of pores relate to the ease of the biomaterial to facilitate host 
tissue in-growth, facilitating vasculature and enhancing nutrient exchange 
kinetics. To this extent, several studies have demonstrated the importance of 
macropores (larger than 100 µm) to enhance tissue penetration and bone 
formation. Whether or not this is a pre-requisite for bone induction is still 
unknown, but it has been reported that the optimal pore size should be around 
300 µm with interconnectivity to enable adequate vascularisation. Moreover, 
microporosity (smaller than 10 µm) has also been implicated in enhancement 
of biomaterial osteogenicity. Habibovic et al. highlighted this by 
demonstrating that elevated microporosity in BCP ceramics resulted in ectopic 
bone formation in a goat model[66]. Microporosity directly influences the 
biomaterial’s roughness, and hence surface free energy. Ionic compounds, 
especially bioceramics, are dependent on this characteristic for apatite layer 
re-precipitation, which in turn affects biomaterial osteoconductivity and 
osteointegration. Clearly, the use of a biomaterial with high porosity with 
interconnectivity and a combination of macro and micropores will be 




beneficial for bone tissue regeneration and host tissue integration. However, 
the specification of these parameters is limited by mechanical constraints. 
Biomaterials begin to lose mechanical strength and hardness with the inclusion 
of pores, and this represents a compromise between mechanical requirements 
and bioactivity of the biomaterial.  
The design of a biomaterial for bone tissue engineering involves an 
interdisciplinary approach, which begins with an intimate appreciation of the 
bone biology and bone healing mechanisms. Through this, a thorough set of 
considerations can be established with respect to the biocompatibility and 
bioactivity of the biomaterial. These considerations encompass deliberations 
to the selection of materials, combining the properties of various types in the 
synthesis of a composite with complementary properties to enhance its 
bioactivity, as well as biofunctionality. Engineering techniques of 
manipulating the surface properties of the biomaterial can be employed to 
elicit specific biological response that enhances bone regeneration. This can be 
achieved through nanosurface topology, as well as degradation characteristics 
so the bone remodelling process can be allowed to occur, which result in 
proper host-tissue dynamics that responds appropriately to the required stimuli. 
In addition, attention should be paid towards designing the porosity, 
interconnectivity and pore size of the biomaterial so as to ensure adequate 
vascularisation, bone ingrowth and osteogenicity. Nevertheless, biomechanical 
functions of maintaining structural integrity and sustaining normal mechanical 
loads during the healing phase should be taken into account as well to prevent 
structural failure at the healing site. While these considerations can present 




conflicting requirements, the effect of these compromises may represent ideal 
conditions for bone remodelling to occur and the result is a biomaterial with 
high osteointegration, and responds dynamically to the required load. 
2.2.3 Bioceramics 
As alluded to in the previous sections, bioceramics play a central role in the 
development of bone tissue engineered constructs. They have been extensively 
used in bone grafts and bone graft substitutes due to their excellent 
biocompatibility, and osteoconductivity[67, 68]. When incorporated with 
growth factors, these bioceramics can exhibit osteoinductivity[69, 70].  
Table 2.5. List of calcium phosphate phases. Abbreviations: calcium-
deficient hydroxyapatite (CDHA), precipitated HA (pHA). [71] 
Name Symbol Formula Ca/P Mineral 
Monocalcium phosphate 
monohydrate 
MCPM Ca(H2PO4)2·H2O 0.50 - 
Dicalcium phosphate DCP CaHPO4 1.00 Monetite 
Dicalcium phosphate 
dihydrate 
DCPD CaHPO4·2H2O 1.00 Brushite 





1.50 – 1.67 - 
x = 1 CDHA Ca9(HPO4)1(PO4)5(OH) 1.50   
x = 0 HA Ca10(PO4)6(OH)2 1.67   
Amorphous calcium 
phosphate 
ACP Ca3(PO4)2·nH2O where 
n = 3–4.5; 15–20% H2O 
1.50 - 
Monocalcium phosphate MCP Ca(H2PO4)2 0.50 - 
α-Tricalcium phosphate α-TCP α-Ca3(PO4)2 1.50 - 
β-Tricalcium 
phosphate** 
β-TCP β-Ca3(PO4)2 1.50 - 
Hydroxyapatite HA Ca10(PO4)6(OH)2 1.67 Hydroxyapatite 
Tetracalcium phosphate TetCP Ca4(PO4)2O 2.00 Hilgenstockite 




Among the most commonly researched bioceramics (Table 2.5) are calcium 
phosphates, with particular attention focused on hydroxyapatite (HA) and β-
tricalcium phosphate (β-TCP). Solubility of β-TCP is much higher than HA, 
and thus β-TCP is termed a bioresorbable ceramic. Development of biphasic 
calcium phosphate (BCP)-based biomaterials consisting of HA and β-TCP[72, 
73] are also of interest to control the degradation properties. Table represents 
an overview of the different calcium phosphates and their properties. Since 
this report is concerned with the long-term culture and implantation of bone 
tissue engineered constructs, stability is of great concern, and thus HA will be 
the subject of attention. A more detailed review of β-TCP and BCP can be 
obtained from other references[74-77]. 
2.2.4 Hydroxyapatite 
Hydroxyapatite is a biocompatible ceramic produced through a high-
temperature reaction and is highly crystalline form of calcium phosphate. The 
nominal composition of this mixture is Ca10(PO4)6(OH)2 with a calcium-to-
phosphate atomic ratio of 1.67. The most unique property of this material is 
chemical similarity with the mineralised phase of bone; this similarity 
accounts for their osteoconductive potential and excellent biocompatibility[78, 
79]. Calcium hydroxyapatite/tricalcium phosphate (60/40) provide a structure 
or scaffold which can have a close interface with adjacent bone and have a 
limited application in the treatment of load-bearing segmental bone defects but 
did not fail at the early stages of implantation[80]. 




HA has higher stability in aqueous media than other calcium phosphate 
ceramics within a pH range of 4.2–8.0. The crystal structure of HA can 
accommodate substitutions by various other ions for the Ca2+, PO43- and OH- 
groups. The ionic substitutions can affect the lattice parameters, crystal 
morphology, crystallinity, solubility and thermal stability of HA. For example, 
the F-or Cl- can substitute for the OH- group while CO32- can substitute for the 
OH- (Type A) or the PO43- (Type B) group. In the case of carbonate 
substituted HA (CHA), for both substitutions, the ionic lattice undergoes 
crystallographic changes to accommodate the imbalance in charge. This 
results in a reported increased bioactivity of CHA due to increased 
solubility[81]. 
!
Figure 2.6. X-ray diffraction profiles: (A) enamel (a), dentine (b) and bone 
(c) mineral (carbonate apatites) (B) ceramic HA (a), bone (b). (C) FTIR 
spectra of ceramic HA (a) and bone mineral.[82] 
The rationale for developing HA biomaterials is its similarity in composition 
with bone material or bone apatite. XRD profile and FTIR (Fig. 2.6a ) 
spectrum of synthetic HA compared with bone shows similarities and 
differences in crystallinity (Fig. 2.6b ) and composition, e.g. presence of 
carbonate in bone apatite (Fig. 2.6c )[82] 




HA can be derived from both biologic and synthetic origins. Biologic HA can 
be obtained from coral, bovine bone or marine algae. There are various 
methods to obtain HA from biologic sources but the review is beyond the 
scope of this report. 
HA can be fabricated synthetically from the following methods: i) Solid state 
reactions, ii) Hydrothermal reaction, iii) Sol-gel, and iv) Wet Precipitation 
i) Solid State Reaction[82] 
Calcium compounds are mixed thoroughly, compressed and sintered above 
950°C. 
6CaHPO4 + 4Ca(OH)2 ! Ca10(PO4)6(OH)2 + 6H2O 
Reaction of dicalcium phosphate anhydrous (DCPA) and calcium hydroxide to 
form hydroxyapatite and water  
3Ca3(PO4)2 + Ca(OH)2 ! Ca10(PO4)6(OH)2 
Reaction of beta-tricalcium phosphate (β-TCP) and calcium hydroxide to form 
hydroxyapatite  
ii) Hydrothermal reactions[83] 
In Figure 2.7, the mechanism model of hydrothermal method of HA synthesis 
is illustrated. HA can be synthesised by hydrothermal treatment of calcite 
crystals in H3PO4 suspensions at 120 °C or 180 °C, according to the equation:  
 10CaCO3 + 6(NH4)2HPO4 + 2H2O --> Ca10(PO4)6(OH)2 + 6(NH4)2CO3 + 4H2CO3 
Typical treatment time of 24 h under high pressure of approximately 100MPa 
produced single phase hydroxyapatite powder. Hydrothermal reactions are 
usually slow.  





Figure 2.7. Mechanism model of hydrothermal convection of calcite 
crystals into HAp crystals[83] 
!
iii) Sol-gel preparation[84] 
 
This method is used to produce hydroxyapatite granules of the highest 
stoichiometric pureness. Referring to figure 2.8, this method starts from 




molecular precursors dissolved in solutions that are organic solvents. These 
organic molecules include the desired inorganic atoms. This association of 
inorganic and organic parts is commonly called a metal-organic compound. 
First step involves polymerization, then subsequently a colloidal condensation 
of the gel micelle. Polymerization involves condensation coupling. Use of 
alkoxides is very popular as they can be obtained easily. Use of calcium 
acetate monohydrate as source of calcium ions and ammonium-hydrogen 
phosphate as the phosphorus precursor both dissolved in a small amount of 
distilled water. Aqueous solutions of ethylene diamine tetra-acetic acid 
(EDTA) or tartaric acid (TA) were used as chelating agents in the sol-gel 
synthesis of hydroxyapatite. In figure 2.9, HA produced using the EDTA route 
are composed of grains with no regular shape, and with irregular surface 
texture. In figure 2.10, HA produced using the TA route results in formation of 
nicely shaped ultrafine elongated particles (microrods) with average grain size 
of 5 µm. 
HA synthesis using the sol-gel method is usually used to form thin film 
coatings, which are used in metallic coating biomedical applications. 
iv) Wet Precipitation[85] 
Wet precipitation is the most preferred method as it is the most established and 
easiest to synthesise.  
5Ca(OH)2 + 3H3PO4 ! Ca5(PO4)3OH + 9H2O 
Reaction occurs when H3PO4 is added drop wise in a Ca(OH)2 aqueous 
suspension. Calcium hydroxide is in fact very weakly soluble in water, and 




consequently the reaction takes place between the PO43- ions diffused from the 
drop plunged into the suspension and the surface of the colloidal particles. The 
alkaline pH of the aqueous environment allows the hydroxyapatite to be stable, 
and is maintained by the complete dissociation of a few dissolved molecules 
of Ca(OH)2 which is a strong base. 
Hydroxyapatite forming reactions is linked to the rate of: i) Diffusion of the 
ionised phosphatic ionic groups (PO43-, HPO42-, H2PO4- and H3PO4 itself) 
connected to each other by well known simultaneous equilibra, ii) dissolution 
of Ca(OH)2 as well as that of Ca2+ ions into the aqueous solution, iii) 
migration of the ionised phosphate groups within the colloidal grains of 
Ca(OH)2, and iv) success of the transformation depends on the value of the 
local pH, even if the overall solution may remain alkaline. 
Presence of CO32- may replace the anionic component of the calcium 
compounds and give rise to more stable CaCO3. This may then result in the 
production of other kinds of phosphates, including the carbonate apatites. 
Presence of CO2 can be prevented by promoting reaction inside a reactor. All 
the foreign ions present in the synthesis solution may lead to the formation of 
molecules different from the hydroxyapatite molecule. These molecules may 
aggregate and eventually crystallise in foreign phases, or may induce the 
formation of other phases and hinder the formation of hydroxyapatite, or may 
associate in the precipitation of hydroxyapatite crystals and, by co-
precipitating, replace one or other of the component groups in their regular 
group. If these replacements occur, defective hydroxyapatite is produced in 




which a number of empty sites are present inside the crystal lattice. To favour 
the escape of foreign ions from the hydroxyapatite lattices and at the same 
time to increase the thickness and the rate of crystallisation of synthesised 
hydroxyapatite, it is essential to allow the digestion of the solution once the 
synthesis has been completed, after addition of the last drop which brings 
about the correct stoichiometric ration between Ca2+ and PO43- (in molar ration 
of 5/3) 
Digestion involves maintaining the solution at rest of about 37 °C for at least 
48 hours. Highest degree of crystallinity was reached when the solution 
approached boiling temperature of about 97 °C. 
 
Fig 2.11. SEM microgragh of (a) as-precipitated HA and (b) after the 
aging process (100,000x)[85]  
SEM high magnification micrographs (Fig 2.11a) show that the precipitated 
HA consists of small rod-like or platy particles. Aging the suspension leads to 
the growth of the particles and changes the morphology to a more equi-axed 
status (Fig 2.11b). 




Typical HA powders synthesised via wet precipitation typically correspond 
closely to standard XRD pattern (Fig. 2.12) of pure HA (JCPDS 9-432), with 
increasing crystallinity as heating temperature is increased. 
!
Fig 2.12. XRD pattern of synthesised hydroxyapatite as precipitated (a), 
heating at 850°C (b) 1200°C (c). Peaks of hydroxyapatite (JCSPDS 9-432) 
2.3 Fabrication of spherical bioceramic particles 
2.3.1 Alginate as a matrix polymer for microencapsulation  
!
Fig 2.13. The monomers of Alginate[86] 
Alginates are naturally occurring polysaccharides that have been finding 
increasing applications in the biotechnology field. They belong to a family of 
linear copolymers of β-D- mannuronic acid (M unit) and α-L-guluronic acid 
(G unit) residues (Fig 8), which can be arranged in different proportions and 




sequences along the polymer chain. The G- and M- units are joined together in 
one of three blocks: GG... , MM... , and MG.... (Fig 9). The proportion, 
distribution, and length of these blocks determine the chemical and physical 
properties of the alginate molecules[87]. 
2.3.1.1 Rheology 
The viscosity of an alginate solution depends on the concentration of alginate 
and the length of the alginate molecules, i.e. the number of monomer units in 
the chains. The longer the chains the higher the viscosity at similar 
concentrations (Figure 2.14). Length of chains can be contolled by the degree 
of polymerisation (DP). DP is directly proportional to the alginate’s molecular 
weight, ranging from 80 to 750, corressponding to a molecular weight from 
14000 to 132000. A DP of 80 is considered low viscosity, 400 classified as 
medium viscosity and 680 as high viscosity[88]. 
!
Fig 2.14  Three basic blocks of Alginate polymer chains, the MM-block 
(left), GM-block (middle), and GG-block (right), which may join together in 
different proportions, distribution and length.[89] 
!





Figure 2.15. (a) Viscosity as a function of Concentration of Alginate in 
Water. (b) Viscosity as a function of Temperature. Low viscosity: 80 DP 
alginate, medium viscosity: 400 DP alginate, and high viscosity: 680 DP 
alginate.[90] 
Upon dissolving alginates in water, the molecules hydrate and the solution 
gain viscosity. The dissolved molecules are not completely flexible; rotation 
around the glycosidic linkages in the G-block regions is somewhat hindered, 
resulting in a stiffening of the chain. Solutions of stiff macromolecules are 
highly viscous. Temperature defines the energetic state of any chemical 
molecule. Hence, temperature influences the response of alginates to shear 
forces. As a general rule, temperature increases of 1°C lead to a viscosity drop 
of approximately 2.5% (Fig 2.15). 
2.3.1.2 Gelation of Alginate 
Sodium alginate forms relatively stable hydrogels through ionotropic gelation 
in the presence of many multivalent ions, being Ca2+ the most widely used. 
The crosslinking process can be carried out under very mild conditions, at low 
temperature and in the absence of organic solvents, and hydrogels of different 
shapes can be prepared. Divalent cations of Ca2+ cooperatively bind between 
the G-blocks of adjacent alginate chains, creating ionic interchain bridges 
which cause gelling of aqueous alginate solutions (Fig 2.16).[91] 





Fig 2.16. Calcium binding site in G-blocks[91] 
 
In the “egg-box model”, the divalent calcium cation, Ca2+, fits into the G block 
structure like eggs in an egg box (Fig 13). This binds the alginate polymers 
together by forming junction zones, resulting in gelation of the solution[92]. 
!
Fig 2.17. Egg-box model of Alginate gel formation[91] 
2.3.2 Microsphere Preparation 
Several therapeutic agents, including antibiotics, enzymes, growth factors and 
DNA, have already been successfully incorporated in alginate gels, retaining a 
high percentage of biological activity. Alginate plays two roles in the 
microsphere preparation: As a vehicle to form spherical shape particles, and as 




pore inducing agent in the sintering process, all of this without any 
modification on HA. 
Ca-Alginate microspheres are generally prepared by two methods: Drop wise 
extrusion of aqueous alginate into a solution of Calcium salt[93-95], and 
emulsification method under gentle stirring [96-98]. Particles produced by the 
first method are generally large (more than 1mm) and the attempts to obtain 
smaller particles have resulted in various complications such as clogging and 
high costs associated with special extrusion devices. However, microspheres 
produced in this route exhibit high spheroidicity and consistent size. 
The second method is less commonly used due to the high viscosity associated 
with the starting alginate solutions. In addition, the resulting microspheres are 
generally non-spherical with wide variations in size, with high tendency to 
clump into aggregates. 





Fabrication and Characterisation of Apatite 
Microcarriers 
3.1 Introduction 
Among the bioceramics being considered for bone implant applications, 
apatite has been prominently featured due to its similarity to human bone[99] 
and favourable properties of excellent biocompatibility and 
osteoconductivity[74]. Applications of apatite based biomaterials range from 
thin coatings on metallic implants[100, 101] to drug release platforms[102, 
103]. One of the most promising area of development for apatites is its use as 
a bone graft substitute, in which there is a growing demand due to a an 
increasing gap in the unmet needs in the treatment of dental or bone defects 
caused by trauma and diseases[104]. Apatite based bone graft substitutes are 
available in various forms: granules, blocks, cements, non-setting pastes 
(putties), foams, and films (membranes). Most commercially available bone 
graft substitutes contain apatite in the form of granules, because of their ease 
of fabrication, abundance, and proven clinical efficacy[105, 106]. Moreover, 
non-granular apatites do not have the necessary properties for them to be 
functional in clinical applications. For example, porous blocks can only be 
used in situations where the defect is geometrically well-defined such as in an 
open-wedge tibia osteotomy[107], or use of pastes involving apatite 
nanoparticles can result in implant migration, due to loss of cohesion and rapid 
material resorption such that its mechanical function is lost[108]. Through and 
understanding of the bone biology and design considerations of a biomaterial, 




it is apparent that shape, size, porosity and surface morphology of the apatite 
granules are key towards ensuring its relevance in application, facilitating new 
bone tissue formation, while allowing for blood vessel in-growth[109]. 
Spherical particles allow for an optimal surface area to volume ratio for 
cellular adhesion and proliferation, and allow for ideal hydrodynamic response 
in dynamic flow conditions, which are particularly relevant in bioreactor 
culture systems[110]. In addition, spherical particles allow for better flow 
characteristics, which improve the injectability of these materials during non-
invasive procedures[111]. Size of these spherical particles have been 
suggested to be within 200 – 300 µm[112, 113], with presence of microscale 
and macroscale pores which are interconnected[66], so as to direct a 
favourable local and systemic response towards new bone and blood vessel 
formation. 
In view of these considerations, the fabrication, characterisation and 
optimisation of spherical, porous apatite based microcarriers will be described. 
It is envisioned that these apatite microcarriers will possess the 
physicochemical properties that promotes, facilitates and maintains bone 
regeneration, thus delivering a tissue engineered biomaterial that can 
adequately meet the needs of the dental and orthopaedic community. 
3.2 Materials and Methods 
3.2.1 Synthesis of phase-pure HA 
HA was synthesized via a wet precipitation route. Calcium hydroxide [Ca 
(OH)2] and orthophosphoric acid (H3PO4) were weighed and dissolved in 
deionised (DI) water to form solutions. 1 l of an aqueous H3PO4 (0.6 M) was 




added dropwise into 1 l of an aqueous Ca (OH)2 (1 M) under continuous 
stirring at 24 °C. Concentrated ammonia solution was added to maintain a pH 
value above 10.5. The solution was left to age for 2 weeks before subjecting it 
to an autoclave process for 2 h. The resulting precipitate was then dried in an 
oven at 70 °C for 12 h. 
3.2.2 Synthesis of apatite microcarriers 
A schematic representation of the synthesis process has been provided (Figure 
3.1). Varying proportions of Na-Alg and HA powders were used (Table 3.1), 
and the resulting solution was extruded dropwise into a CaCl2 crosslinking 
solution of varying concentrations using a droplet extrusion device. Na-Alg 
was dissolved in DI water for 30 minutes using a magnetic stirrer until total 
homogenization was achieved. HA, powder was then added to the Na-Alg 
solution, and stirred at 50 °C for 8 h using a hot plate stirrer, to ensure 
thorough homogenization. The solution containing HA and Na-Alg was 
extruded dropwise using a roller pump into CaCl2 crosslinking solution, 
whereby spherical microcarriers were formed instantaneously. 
The solution containing HA-Alg microcarriers and CaCl2 was then allowed to 
mix for 2 h under gentle magnetic stirring to ensure crosslinking completion.  
HA-Alg microcarriers were retrieved from the solution and washed twice with 
distilled water to remove any CaCl2. These microcarriers were left to dry 
overnight at 24 °C before subjecting to a multi-stage sintering process. 
A multi-stage sintering profile (Figure 3.2) was designed so as to produce 
microcarriers with better characteristics. The stages were designed after the 




melting temperature of Alg were obtained so as to allow for a more gradual 
burnt-off as well as to allow for longer time for the necking process between 
HA particles to occur.  
 
Figure 3.1. Synthesis process of apatite microcarriers. Apatite powder is 
dispersed in an alginate solution and mixed to ensure thorough 
homogenisation. The Apatite-Alginate solution is then extruded drop-wise 
through an electrically controlled valve that ensures consistent size into a 
calcium chloride cross-linking solution. The resulting microbeads are then 
washed, dried, and subjected to a multiple-staged sintering process to 1150°C. 
Alginate serves as the matrix to structure nano-crystalline apatite into a 
microsphere, and also allows the formation of pores when it is burnt off 




Table 3.1. Apatite microcarriers fabricated using different Alg 
concentrations, HA contents and CaCl2 concentrations 
Sample Alg concentration HA content CaCl2 
concentration 
 (g/ml) (wt.%) (mol/dm3) 
1 0.0128 20 0.1 
2 0.015 20 0.1 
3 0.03 20 0.1 
4 0.03 40 0.1 
5 0.03 40 0.5 
6 0.03 50 0.1 
7 0.03 50 0.5 
8 0.03 40 0.5 
!
 
Figure 3.2. 4-stage sintering profile for HA-Alg microcarriers 
!




3.2.3 Characterisation of apatite microcarriers 
3.2.3.1 Optical microscopy analysis 
The size of the microcarriers was estimated using an optical microscope with a 
calibrated built-in measurement scale. The mean diameter was determined 
from a sample of twenty microcarriers. 
3.2.3.2 Scanning electron microscopy analysis 
The microcarrier’s morphology was analysed using a field emission scanning 
electron microscope (FE-SEM, Hitachi S-4300), operating at an accelerating 
voltage of 15 kV. The samples were sputtered-coated with a thin layer of gold 
before examination. 
3.2.3.3 Energy dispersive X-ray spectroscopy analysis 
Preliminary surface characterization of the apatite microcarriers was analysed 
using an energy dispersive X-ray spectroscopy (EDS). Samples were loaded 
into the SEM machine operating at an accelerating voltage of 15 kV, and a 
working distance of 10 mm. The elemental quantitative analysis used an 
automatic background subtraction, and a ZAF correction matrix has been used 
to calculate the elemental composition in weight percentage. 
3.2.3.4 Thermogravimetric analysis 
Thermogravimetric analysis (TGA) was conducted for the HA-Alg 
microcarriers to determine its thermal stability and burnt-off characteristics. 
Sample weight was 14 mg, and a platinum pan was used. TGA was conducted 
between 25 and 1200 °C at a heating rate of 10 °C/min, in an argon 
atmosphere. 
! !




3.2.3.5 Differential scanning calorimetric analysis 
Differential thermal analysis (DTA) analysis was conducted to determine the 
melting temperature of HA-Alg microcarriers. 22 mg of HA-Alg microcarriers 
was added onto an aluminium pan, and heated from 25 to 500 °C at a rate of 
10 °C/min. 
3.2.3.6 X-ray diffraction analysis 
The phase composition of apatite microcarriers was investigated using an X-
ray diffractometer (XRD, Shimadzu X-ray diffractometer, Model 6000). The 
microcarriers were crushed and compacted before loading onto the machine. 
CuKα radiation (λ = 1.5406 nm) at a scanning rate of 0.3 °/min was used over a 
2θ range of 20 – 40 °, with a sampling interval of 0.05 °, operating at 30 mA 
and 40 kV. Phases were identified by comparison of the experimental data 
with the reference data from the International Centre for Diffraction Data. 
3.2.3.7 Fourier transform infrared spectroscopy analysis 
Chemical characterisation was performed using a fourier transform infrared 
spectroscometer (FTIR, Varian 3100 spectrometer). For this purpose, apatite 
microcarriers were crushed and analysed using potassium bromide pellets. A 
wavelength ranging from 400 to 4000 cm-1 with a spectral resolution of 16cm-1 
was used.   
! !





3.3.1 Pre-sintered HA-Alg microcarriers 
The first step to apatite microcarrier fabrication involved HA-Alg bead 
formation. The following results report on the physical morphology of HA-
Alg beads prepared under various settings. 
3.3.1.1 Low HA content, low Alg concentration 
The initial batch of HA-Alg beads was fabricated using 20 wt.% HA and 
0.015 g/ml Alg. Flow through the tubing during droplet extrusion was rapid as 
the solution exhibited low viscosity. The fabricated beads in the 0.1 M CaCl2 
solution appeared to have good spheroidicity, and they remained intact after 
removing from the solution and washed. However, upon drying, HA-Alg 
beads appeared to be more disc-like, with flattened structure. This could be 
attributed to excessive water loss from the beads during drying, and 
insufficient Alg content to maintain its integrity of the bead. The appearance 
of white specks within most HA-Alg beads indicated insufficient 
homogenisation of HA within the Alg matrix. The size of the pre-sintered 
particles averaged 1.8 mm, and displayed high tendency to clump together and 
form agglomerates during drying. 
3.3.1.2 High HA content, high Alg concentration 
After the initial batch of fabrication, HA-Alg beads were fabricated using 40 
and 50 wt.% HA. A higher concentration of Alg solution (0.03 g/ml) was also 
used. Beads that were formed during the crosslinking process maintained their 
shape after drying, and were more spherical compared to beads prepared using 
low Alg concentration. In addition, the beads did not tend to aggregate. The 




variation of HA content between 40 and 50 wt.% did not yield any significant 
change in size. The size of the beads was measured to be 1.4 mm. This value 
was slightly smaller than beads formed using low Alg concentration, which 
could be attributed to better crosslinking within the Alg polymer chains. 
Some HA-Alg beads were crushed and examined using FE-SEM. The internal 
morphology of the beads revealed specks of HA embedded within the Alg 
matrix (Figure 3.3). EDS analysis confirmed that the grey areas consisted 
mainly of carbon and oxygen whilst the brighter specks contained calcium and 
phosphorus. The HA distribution within the matrix was homogeneous, with no 
obvious aggregation of HA particles being observed in any part of the bead. 
!
Figure 3.3. SEM micrograph of crushed pre-sintered HA-Alg microcarrier 
(50 wt.% HA, 0.03 g/ml Alg) to show internal morphology 
!
3.3.1.3 Effect of CaCl2 concentration 
To investigate the effect of CaCl2 concentration on bead formation, two 
batches of HA-Alg suspension (40 wt.% HA, 0.03 g/ml Alg) were extruded 
into crosslinking solution of 0.1 and 0.5 M CaCl2, respectively. 




HA-Alg beads prepared using 0.1 M CaCl2 demonstrated pits and furrows 
(Figure 3.4a). When a higher concentration of 0.5 M CaCl2 was used, none of 
the beads exhibited pits (Figure 3.4b). This phenomenon suggested that using 
a low concentration of CaCl2 could result in incomplete crosslinking of the 
beads. Beads prepared using 0.1 or 0.5 M CaCl2 had an average size of 1.4 
mm. 
!
Figure 3.4. Pre-sintered HA-Alg microcarriers fabricated using (a) 0.1 M 
and (b) 0.5 M CaCl2 crosslinking solution 
3.3.2 Thermal analysis 
To investigate the thermal stability of HA-Alg beads, TGA (Figure 3.5a) and 
DTA (Figure 3.5b) were conducted for beads containing 40 wt.% HA and 0.03 
g/ml Alg. The HA-Alg beads lost 60 % by weight in total during the sintering 
process from 23 to 1200 °C. Weight loss occurred almost immediately at 50 
°C, and continued all the way to about 1000 °C. The first major weight loss 
occurred at 200 °C, which registered a weight change of approximately 35 %. 
This corresponded to the rupture of the Alg monomers as well as the removal 
of water within the Alg beads. A second weight loss occurred approximately 
400 °C, which accounted for 20 % weight loss. A third weight transition 
occurred at 640 °C, which accounted for a 5 % weight loss. The second and 




third weight losses could be due to the thermal decomposition of sodium and 
calcium Alg complexes to intermediate compounds and subsequently, 
breakdown of these intermediates to metal oxides. The suggested mechanisms 
were as follows18: 
At temperature ≤ 200 °C, 
C12H14O11M.xH2O  →  C12H14O11M  +  xH2O 
At temperature > 200 °C, 
C12H14O11M  +  10CO2  →  M(COO)2  +  10CO2  +  7H2O 
At temperature > 350 °C, 
M(COO)2  →  MO (metal oxide)  +  2CO2 
The stages of decomposition were supported using the DTA graph. The initial 
drop in energy value up to 82 °C was an endothermic process, which could be 
explained by the absorption of energy by the beads to break the bonds needed 
for the liberation of water molecules. A small peak observed at around 200 °C 
corresponded to the stage where the HA-Alg broke down into an intermediate 
metal-oxalate. Subsequently, the strong exothermic peak at 420 °C 
corresponded to the third stage where the metal-oxalate began to form the 
more stable metal oxide. Beyond 1000 °C, no further weight change occurred, 
and the sample remained stable up to 1200 °C. 





Figure 3.5. Thermal analyses of HA-Alg microcarriers (40 wt.% HA, 0.03 
g/ml Alg). (a) TGA graph, and (b) DTA graph 
!
3.3.3 Sintered apatite microcarriers 
HA-Alg microcarriers containing 40 wt.% HA and 0.03 g/ml Alg were 
sintered using a 4-stage sintering profile (Figure 3.2). SEM image (Figure 3.6a) 
revealed that the sintered microcarriers displayed good spherical morphology, 
with a mean diameter of about 1 mm. Some microcarriers displayed 
occasional surface cracks. The cross-sectional view demonstrated that these 
microcarriers displayed high interconnectivity, and HA necking regions were 
clearly visible (Figure 3.6b). Distinct micropores could also be observed. 
Similar to the surface, the inner core displayed highly packed, interconnected 
HA structure that was rough and porous. 
!
Figure 3.6. Sintered apatite microcarrier (40 wt.% HA, 0.03 g/ml Alg). (a) 
Normal view, and (b) Cross-sectional view 
(a)!




3.3.4 XRD analysis 
XRD was done for the autoclaved HA powder, and sintered apatite 
microcarriers containing 40 wt.% HA (Figure 3.7). The results were then 
compared with the standard XRD patterns of HA (JCPDS 9-432). All the 
peaks corresponded to that of apatite. The peaks obtained for the sintered 
microcarriers were well-defined and distinct, indicating that apatite had a good 
crystalline phase. By comparing the XRD patterns of the sintered 
microcarriers with the HA powder that was used to synthesise the 
microcarriers, it could be seen that after sintering, the peaks obtained from the 
microcarriers represented a more crystalline phase, suggesting that an increase 
in temperature increased the amount of crystallinity. Phases corresponding to 
tricalcium phosphate and tetracalcium phosphate were not observed, 
confirming that HA in the microcarriers remained chemically stable during the 
sintering process. 
!
Figure 3.7. XRD patterns of (a) as-synthesised apatite powder and (b) 
sintered apatite microcarriers. Asterisks indicate phases of apatite   




3.3.5 FTIR analysis 
FTIR was conducted for the as-synthesised apatite powder, and sintered 
microcarriers containing 40 wt.% HA (Figure 3.8). Table 3.2 lists the band 
assignments of the spectra. For the apatite microcarriers, sharp bands at 567, 
603 and 632 cm-1 were detected and corresponded to the v4 phosphate bands. 
These peaks were also present in the autoclaved HA powder, but were less 
distinct, implying that crystallinity increased with sintering temperature. 
Furthermore, sharp bands at 960, 1047 and 1093 cm-1 were seen for both HA 
powder and microcarriers, which were definitive of the v3 phosphate band, 
present in HA. The characteristic bands of the COO- groups at 1318, 1420 and 
1619 cm-1 as well as the –CCH group at 809, 903 and 945 cm-1 were absent, 
indicating that there was no significant contamination of Alg residues being 
present19. Referring to HA powder, the broad band at 3500 cm-1 suggested that 
there were inclusions of water as well as structural hydroxyl group. Upon 
sintering, this band resolved into a sharp peak at 3571 cm-1, which could be 
seen for the sintered microcarriers. This peak was the characteristic band for 
hydroxyl stretching. 
Bands present at 875, 1423, 1454 and 1641 cm-1 corresponded to the presence 
of a carbonate phase, implying that carbonate had been incorporated into the 
HA structure. This effect could be due to the decomposition of Alg whereby 
carbonate ions substitute for either phosphate groups or hydroxyl group. 





Figure 3.8. FTIR spectra of (a) as-synthesised apatite powder and (b) 
sintered apatite microcarriers. Bands of phosphate and carbonate are labelled. 
!











3571 3000 – 3800 3572 
Carbonate ν3 1650 1454 1454 
1417 1423 - 
Phosphate ν3 1091 - 1093 
1041 1047 1047 
Phosphate ν1 961 960 960 
Carbonate ν2 873 876 876 
Phosphate ν4 629 629 633 
603 604 604 
567 567 567 





During the fabrication of apatite microcarriers, Alg concentration, HA content 
and CaCl2 were factors that affected the overall morphology of the 
microcarriers. A low Alg concentration (0.01 g/ml) resulted in insufficient HA 
encapsulation and excessive water loss during the drying process would cause 
the microcarriers to agglomerate and flatten. Increasing Alg concentration 
increased microcarrier integrity during drying. Apatite microcarriers formed 
using 0.03 g/ml Alg was found to be the optimal concentration as the 
microcarriers that resulted after drying were well rounded. Next, low HA 
content (20 wt. %) resulted in microcarriers that were inhomogeneous as HA 
were not evenly distributed throughout the microcarrier. This caused the 
sintered apatite microcarriers to have an irregular shape with large variation in 
size. By increasing HA content to 40 wt.%, apatite particles seemed well 
distributed, and the resultant sintered microcarriers have a generally spherical 
shape. An important point to note would be that as Alg concentration and HA 
content increased, viscosity of the HA-Alg increased, and this would lead to 
an increase in the incidence of tube occlusions. The authors have found that 
0.03 g/ml Alg and 40 wt. % HA represented the optimal parameters for 
obtaining spherical sintered apatite microcarriers with minimal risks of tube 
occlusions.  
CaCl2 concentration determined the extent to which crosslinking occurred 
during the gelation process. A low CaCl2 concentration (0.1 M) resulted in 
insufficient Ca2+ ions available for crosslinking, causing apatite microcarriers 
to have deep furrows and pits, which would result in high susceptibility to 




brittle fracture during the sintering process. Using a 0.5 M CaCl2 eliminated 
this effect, and the stronger crosslink produced during ionotropic gelation 
promoted denser HA particle-particle packing, thus creating greater necking 
during the sintering process. This would be beneficial towards maintaining 
structural integrity of the sintered apatite microcarriers.  
TGA analysis identified the different stages in which decomposition of the 
Alg occurred. By designing a multi-stage sintering profile, sufficient time 
would be allowed for the different reactions to take place. This would be 
crucial in obtaining pure apatite microcarriers with minimal impurities. 
Furthermore, by allowing sufficient time at the hold temperatures, defects and 
cracks in the sintered apatite microcarriers could be minimised.  
While CaCl2 concentration and sintering profile could be controlled to 
minimise crack formation, occasional surface cracks can be observed after 
sintering. This could be attributed to non-homogenous cooling experienced by 
the microcarriers during sintering. The outer surface of the microcarrier may 
be undergoing greater contraction due to more rapid cooling compared to the 
inner core of the microcarrier. The uneven contraction causes tensile forces to 
be experienced at the outer surface and this causes a crack to be formed at the 
surface. As the microcarrier cools further, stress concentration at the crack tip 
causes it to propagate inwards, but this does not extend all the way to cleave 
the sphere in half. This is because past the halfway point of the sphere, the 
area of the sphere away from the crack is in compression, thus arresting the 
crack as it progresses.  Furthermore, with the presence of pores in the 




microcarrier, random cracks are inevitable because voids within the 
microcarrier act as stress amplifiers, placing some areas in greater stress than 
others when a force is applied. As the size and shape of each individual void 
cannot be completely controlled, the presence of any adnormally large pore 
could cause the microcarrier to fail by brittle fracture. One way to reduce the 
occurrence of this is by increasing the content of apatite used during 
fabrication, thus reducing pore size and density. However, since presence of 
pores is actually desired in a tissue engineered biomaterial, a balance has to be 
achieved between level of porosity required and maintaining structural 
integrity. 
From the SEM images, the fabricated apatite microcarriers were substantially 
spherical, with a rough surface morphology. These, combined with the 
presence of an interconnected pore structure, would be beneficial towards 
increasing apparent surface area as well as surface energy for protein 
adsorption, which would enhance cellular adhesion. XRD result demonstrated 
that apatite microcarriers consisted of a pure apatite material, with a crystalline 
phase. Undesirable phases such as tricalcium phosphate or tetracalcium 
phosphate, which would otherwise compromise in-vivo stability, were not 
detected. FTIR analysis confirmed that all bands of the apatite microcarriers 
corresponded to functional groups of apatite, without any residual alginate 
functional groups. A phase-pure apatite material would be advantageous 
towards promoting osteoconductivity and its chemical similarity to the mineral 
phase of natural bone would address issues of biocompatibility[67]. 
Furthermore, apatite has low degradation rate, making it an ideal choice for a 




long-term tissue engineered solution that would not only encourage bone 
regeneration, but also undertake part of the defect site’s structural functions as 
the wound site heals. Its high thermal stability also makes it easily 
autoclavable and eliminates theneed for complex sterilization techniques. 
3.5 Summary 
The fabrication technique for apatite microcarriers was reported. This involved 
mixing HA with a solution of Alg. The suspension was then extruded via a 
droplet-extrusion method into a CaCl2 crosslinking solution. Subsequently, the 
HA-Alg microcarriers were subjected to a sintering profile, to produce the 
sintered apatite microcarriers. Various processing parameters such as HA 
content, Alg concentration and CaCl2 crosslinking concentration would 
influence the overall morphology and physicochemical characteristics of the 
microcarriers, and these parameters could be controlled to produce the desired 
apatite microcarriers. The authors proposed that a 40 wt.% HA, 0.03 g/ml Alg 
concentration, 0.5 M CaCl2 crosslinking solution, and a 4-stage sintering 
profile represented the optimal parameters. SEM images revealed that the 
sintered microcarriers displayed a rough surface morphology with presence of 
interconnected pores. In addition, sintered microcarriers displayed high phase-
purity as determined by XRD and FTIR analyses. These properties could be 
ideal for cell adhesion and proliferation. 
 




Chapter 4  
In-vitro Evaluation of Apatite Microcarriers 
4.1 Introduction 
Bone-related injuries and diseases are often debilitating in nature, and while it 
may not be as apparent as acute diseases, the development of these conditions 
can cause a considerable strain on healthcare resources due to the long-term 
care required for treatment and rehabilitation. Traditionally, bone grafts 
(allografts or autografts) are used for the treatment of bone defects. However, 
the lack of availability of suitable donors and sufficient grafts have prompted 
search into tissue engineering solutions to address this growing need. Most 
bone tissue-engineered solutions involve the use of stem cells or scaffolds, or 
a combination of both.  In this regard, mesenchymal stem cells (MSCs) have 
been identified as promising stem cell candidates for bone tissue-engineered 
applications. MSCs are rare multipotent cells, which are readily isolated and 
expanded from bone marrow, with a well-defined osteogenic differentiation 
pathway [114], and demonstrated great potential for tissue engineering 
applications [115]. Existing expansion technique based on culture flasks 
requires trypsin-mediate multiple passages of monolayer cells to achieve cell 
numbers. This method is certainly costly, time-consuming, and susceptible to 
contamination due to numerous passages needed to generate sufficient cells 
for transplantation. Furthermore, the removal of extracellular matrix laid down 
during stem cell expansion by repeated trypsinisation is likely to lead to 
reduced intra-cellular signalling responsible for cell viability, proliferation and 
differentiation [8]. Thus, microcarriers that provide a high surface area for cell 




attachment has generated great interest nowadays[116-118]. The currently 
available microcarriers are made of polymers or glass-based matrices[9, 119], 
mainly designed and developed for in-vitro applications in pharmaceutical 
industries, and may not be suitable for therapeutic implantation. Certainly, the 
need for such technology is potentially huge.  
Here, the use of apatite microcarriers as an alternative to conventional cell 
culture methods is featured. These novel biomaterials offer the advantage of a 
high surface area to volume ratio, which can be utilised in dynamic culture 
conditions for higher cell yield. In addition, the physiochemistry of the 
microcarriers make it particularly relevant for bone tissue engineering 
applications, where MSCs can be expanded, differentiated and implanted in a 
one-step solution to heal bone defects. The purpose of this work is to assess 
the cytocompatibility of the synthesised apatite microcarriers, but culturing 
human foetal mesenchymal stem cells (hfMSCs) on the microcarriers in-vitro. 
In addition, the osteogenic potency of the cell loaded apatite microcarriers will 
also be compared with conventional monolayer culture. 
4.2 Materials and methods 
4.2.1 hfMSC isolation 
Single-cell suspension of foetal bone marrow are prepared by flushing the 
marrow cells out of humeri and femurs using a 22-gauge needle into 
Dulbecco’s modified Eagle’s medium (DMEM, Sigma, USA)-GlutaMAX 
(GIBCO, USA) supplemented with 10 % foetal bovine serum (FBS), 50 U/ml 
penicillin, and 50 mg/ml streptomycin (GIBCO, USA) (referred as D10 
medium), and then plated onto 100 mm diameter dishes at 106 mononuclear 




cells/ml in D10 medium. Media is changed every 2 - 3 days, and non-adherent 
cells are removed, and sub-cultured at 104/cm2 to sub-confluence. hfMSCs at 
passage 3 are used in this study. 
4.2.2 Cytocompatibility study 
Eighteen milligrams of apatite microcarriers and 3.7 mg of Cytodex 3 
microcarriers (GE Healthcare, USA) is added to each well. The calculation of 
weights to be used is based on the total surface area added per well. For the 
apatite microcarriers, this was 0.55 cm2/mg, and 2.7 cm2/mg for Cytodex 3. 
This allows for the total surface area per well of each microcarrier type to be 
10 cm2. 1.0 x 105 cells are then added to each well, such that the seeding 
density for both microcarrier type is 1.0 x 104 cells/cm2. For the adherent 
monolayer culture, 1.0 x 104 cells are added to each 24-well plate such that 
seeding density is 5.0 x 103 cells/cm2. The difference in seeding density 
between microcarrier culture and the adherent monolayer culture is to account 
for the low seeding efficiency of the microcarriers under static conditions, 
such that after 24 h, cells attached on all three surfaces are of similar density. 
Cell viability was assessed quantitatively using PrestoBlue assay (Invitrogen, 
USA), which measures cell viability through the reduction of resazurin to 
resorufin. On the designated time points, 10 % PrestoBlue reagent is added to 
each well and incubated for 25 min at 37 °C. Each time point is measured in 
triplicates. Absorbance at 570 nm, referenced at 600 nm is read using a 
microplate reader (Tecan, USA). The intensity cross-referenced to a standard 
calibration curve of MSC count against absorbance done at the beginning of 
the study to obtain the live cell count at each time point. 




The qualitative analysis of cell viability on apatite microcarriers is performed 
by fluorescein di-acetate/propidium iodide (FDA/PI) staining, where FDA 
stains viable cells green, and PI stains necrotic and apoptotic cell nuclei red. In 
this assay, hfMSCs cultured on apatite microcarriers for 1, 3, 7 and 14 days 
are retrieved from the well, rinsed with phosphate buffer saline (PBS) solution 
and incubated with 8 µg/ml FDA for 10 min. The microcarriers are then 
washed, and incubated with 4 µg/ml PI for 5 min followed by PBS washing 
for two times. Cellular behaviour is also assessed qualitatively by examining 
the cytoskeletal network for any abnormalities. In this assay, hfMSCs cultured 
on apatite microcarriers at day 9 are washed with PBS solution, and fixed in 4% 
paraformaldehyde for 10 min. The microcarriers are then washed and 
permeabilised for 15 min with 0.1 % Triton X-100. The samples are again 
washed and blocked with 2 % bovine serum albumin for 1 h. The washed 
samples are then washed, and stained with 1:500 TRITC-conjugated 
phalloidin. After washing, the samples counterstained with 1:1000 4’-6-
diamidino-2-phenylindole (DAPI) for 5 min to visualize the nucleus. Samples 
are finally viewed under a confocal laser-scanning microscope (CLSM, 
Olympus FV1000). 
4.2.3 Osteogenic differentiation study 
On day 7 of cell culturing, hfMSCs cultured on both apatite microcarriers and 
the adherent monolayer are induced to differentiate down the osteogenic 
lineage by replacing the D10 medium with bone induction media (D10 
medium supplemented with 10 mM β-glycerophosphate, 10-8 M 
dexamethasone and 0.2 mM ascorbic acid). Media is changed every 2 - 3 days. 




Alkaline phosphatase (ALP) plays a key role in signal transduction and 
cellular modulations. ALP is measured using SensoLyte pNPP Alkaline 
Phosphatase Assay Kit (AnaSpec USA). hfMSCs cultured on both apatite 
microcarriers and the adherent monolayer are lysed using the provided lysis 
buffer and Triton X-100. The cell suspension is incubated at 4 °C for 10 min 
under agitation and centrifuged at 2500 rpm for 10 min. The supernatant 
collected is then used for ALP assay. The level of ALP activity is determined 
by absorbance measurements at 405 nm using p-nitrophenyl phosphate 
(pNPP). ALP level is normalized to the total cell count. 
As the primary organic constituent of bone, type I collagen level has been 
linked to bone growth and formation. A MicroVue CICP EIA Kit (Quidel, 
USA) is used to quantitatively determine the levels of C-Terminal of type I 
collagen (CICP) released into the media by the cells. Seventy two hours after 
each media change, the media of each sample is drawn and diluted 1:12 with 
the assay buffer. They are then added to coated strips of purified murine 
monoclonal anti-CICP antibody and incubated for 120 min at 25 °C. Wells are 
washed twice with the wash buffer and rabbit anti-CICP is then added to each 
well, and incubated for another 45 min at 25 °C. Wells are washed 3 times, 
before adding the lyophilized goat anti-rabbit IgG antibody conjugated to 
alkaline phosphatase and incubated for another 45 min at 25 °C. After washing 
for 3 times, a working substrate of pNPP dissolved in a diethanolamine and 
magnesium chloride solution is added to each well and incubated for 30 min at 
25 °C. Finally, a solution of 0.5 N NaOH is added to stop the reaction and the 
optical density at 405 nm is read using the microplate reader. The intensity 




obtained from the samples is compared to a calibration curve obtained using 
known CICP standards to determine the concentration of CICP in the samples. 
CICP values are normalised to total cell count. 
During mineralisation, cells convert calcium ions from the surrounding media 
into insoluble apatite, which is deposited as extra cellular matrix (ECM). The 
amount of calcium ions that the cells take up from the surrounding media can 
thus be measured to determine the level of mineralisation. Calcium ions in the 
samples are quantified using a QuantiChrom calcium assay kit (BioAssay 
Systems, USA). Samples are diluted and incubated with a 
phenolsulphonephthalein dye which forms stable blue coloured complex 
specifically with free calcium in the sample. After the incubation, the intensity 
of the colour is then measured at 575 nm and calcium concentration is 
calculated with a standard curve. Control cell-free apatite microcarriers are 
used as negative controls. Calcium uptake is then calculated by recording the 
initial amount of calcium concentration from the bone induction medium, and 
subtracting it by the calcium concentration of the sample.  Calcium uptake is 
normalised to total cell count.  
4.2.4 Statistical analysis 
Data from each time point is obtained in triplicates. All the data have been 
represented as mean ± standard deviation, and compared using either two-way 
ANOVA or student t-test. A value of p < 0.05 or p < 0.01 or p < 0.001 is taken 
as significant. 





4.3.1 Proliferation and viability of hfMSCs  
!
Figure 4.1. PrestoBlue proliferation assay of hfMSCs cultured on Cytodex 3, 
apatite microcarriers and on conventional monolayer culture (*p < 0.05, ***p < 
0.001) 
PrestoBlue cell viability (Figure 4.1) showed that after 24 h, attachment of 
hfMSCs on apatite microcarriers was 67 %, compared with 50 % for Cytodex 
3 microcarriers. Log expansion phase was achieved between day 3 and 5 for 
adherent monolayer culture and Cytodex 3 microcarriers, and between day 5 
and 7 for apatite microcarriers. Proliferation of hfMSCs on apatite 
microcarriers was slower between day 3 and 5 when compared to Cytodex 3 
microcarriers although apatite microcarriers achieved a 1.4-fold higher cell 
count at day 9. 
PrestoBlue Cell Proliferation Assay Day 1 - 9 (n=3)




























FDA/PI staining observed through CLSM (Figure 4) demonstrated that as the 
hfMSCs proliferate, they remained largely viable throughout the days in 
culture.  Actin staining of hfMSCs cultured on apatite microcarriers was 
conducted on day 7 (Figure 5a) and day 9 (Figure 5b). Through CLSM, cells 
resembled a spindle-like morphology; with actin filaments aligned along the 
curvature of the apatite microcarriers. By day 9, extensive cell bridging across 
microcarriers could be observed. 
!
Figure 4.2. CLSM images of hfMSCs cultured on the apatite microcarriers 
at day 1, 3, 7 and 14. FDA/PI staining was used. Live and dead cells were 
stained green and red, respectively.  





Figure 4.3. Phalloidin-DAPI staining of hfMSC loaded apatite 
microcarriers. Actin filaments were stained red, and nuclei stained blue. (a) 
Image showing extensive cell coverage over the entire carrier. Actin filaments 
were aligned along the curvature of the microcarrier, demonstrating good cell 
adhesion characteristics. (b) Image of a 3-microcarrier aggregate. Cells tended 
to form bridges across each other, creating an interconnected network between 
microcarriers 
4.3.2 Osteogenic potency of hfMSCs  
The osteogenic potential of hfMSCs seeded on apatite microcarriers was 
investigated. Alkaline phosphatase (ALP) activity, type I collagen production 
and calcium uptake were measured at various time points, and compared to the 
adherent monolayer culture. Results (Figures 4.4a-c) demonstrated that the 
osteogenic potential of hfMSCs seeded on apatite microcarriers was enhanced 
as compared to that of the adherent monolayer culture. On day 12, ALP 
expressed by hfMSCs seeded on the apatite microcarriers continued to 
increase, while those seeded on the adherent monolayer culture declined 
sharply after day 9 (Figure 4.4a). Type I collagen production on apatite 
microcarriers was higher at all time points, and production level continued to 
rise after day 9 (Figure 4.4b). Osteocalcin expression by hfMSCs seeded on 
apatite microcarriers exhibited a similar trend, while the adherent monolayer 




culture remained low after an initial increase at day 3 (Figure 6c). On day 12, 
hfMSCs seeded on apatite microcarriers exhibited 1.8 - and 1.5-fold increase 
in type I collagen production and osteocalcin, respectively, relative to the 
adherent to the adherent monolayer culture. Apatite microcarriers without 
hfMSCs (acting as a control) immersed in BM was maintained throughout the 
days in culture, and no significant change in ALP, type I collagen and 
osteocalcin levels (p > 0.05) were detected. 
!
Figure 4.4. (a) ALP assay was performed on adherent monolayer culture 
and apatite microcarriers. On day 12, ALP expression for hfMSCs cultured on 
the apatite microcarriers was 2.7-fold higher than that of the adherent 
monolayer culture. (b) Collagen type I synthesis was measured. hfMSCs 
cultured on the apatite microcarrier produced greater amount of collagen type 
I throughout the culture days. (c) Osteocalcin in BM was measured. 
Osteocalcin expression was the highest for hfMSCs cultured on apatite 
microcarriers. (*p < 0.05, **p < 0.01, ***p < 0.001). Osteocalcin for control 
(not shown) was statistically insignificant (p > 0.05).  





One major obstacle in translating tissue-engineered solutions involving stem 
cell therapy from bench to bedside is the sheer number of cells required for 
successful transplantation. A dose of 3 - 5 x 107 cells/patient is needed to treat 
patients with advanced multiple sclerosis [6] whilst 5.7 - 7.5 x 108 cells/kg is 
required for the treatment of osteogenesis imperfecta [7]. The conventional 
technique to achieve such cell numbers involves the expansion of cells on 
monolayer tissue culture flasks. Given that a standard T-175 flask is able to 
yield only 3.5 - 5 x 106 hfMSCs at confluency, considerable resources have to 
be spent on cell medium, flasks and incubators, making such a method neither 
efficient nor economically feasible. Moreover, at the cellular level, 2D culture 
is insufficient to ensure proper cellular behaviour. Thus, it is necessary to 
develop suitable biomaterials with the appropriate biomolecular cues that can 
mediate and facilitate the response and efficacy of stem cells to their intended 
function.  
On the first issue, microcarriers offer an attractive alternative to conventional 
adherent monolayer culture due to their superior surface area to volume ratio. 
This, combined with the use of bioreactors, allows for a rapid and efficient 
mass production of cells required for stem cell therapy. To address the second 
issue, it is necessary to consider the specific application that the biomaterial is 
intended for. In the case of bone tissue engineering, apatite-based biomaterials 
are ideal candidates because of their close chemical similarity to the mineral 
phase of bone, and beneficial properties of excellent bioactivity and 
osteoconductivity.  




By developing apatite microcarriers, an implantable stem cell-seeded 
microcarrier system for treating bone defects is possible. These microcarriers 
provide a 3D microenvironment with high surface area to volume ratio for cell 
adhesion and proliferation. When used in combination with dynamic culture 
techniques, this cell culture technique simulates the natural in vivo conditions 
of cells[120, 121].  Furthermore, by being apatite-based material, stem cells 
seeded on these microcarriers can be induced to differentiate down the 
osteogenic lineage in situ, and injected directly into the defect site without the 
need for further treatment. This method not only represents a significant 
reduction in steps needed for stem cell therapy, but also presents a non-
invasive solution for treating bone defects, thus reducing risks of infections 
and inflammations. 
In-vitro studies have thus far shown that hfMSC attachment for the apatite 
microcarriers is 1.3-fold higher as compared to Cytodex 3 (a collagen I-
dextran based) microcarriers. The disparity in hfMSC attachment may be 
attributed to several reasons. For apatite, the mechanism underlying cellular 
attachment is governed by the material. When immersed in biological fluids, 
calcium and phosphate ions are released, thereby increasing the degree of 
saturation in the culture medium. This effect will facilitate the reprecipitation 
of CaP layer, which will then incorporate other organic macromolecules from 
the biological fluids. The formation of such a layer will be the initial step 
towards cell attachment. 




On the other hand, cellular attachment on collagen I differs somewhat. For 
collagen, a direct integrin binding to the collagen ligand is involved. hfMSCs 
may express the kind of integrins, which will result in collagen-specific 
binding. This is because fibronectin-ligand receptor integrin types on hfMSCs 
are present in greater in amounts as compared to type I collagen specific 
ones[122, 123]. Already, fibronectin has been identified to promote greater 
hfMSC adhesion than type I collagen[124]. Apatite materials will thus be 
advantageous in this case due to its ability to absorb proteins from the serum, 
which includes fibronectin[125, 126].  
An apatite material with rough surface will further enhance the cellular 
adhesion. In a study conducted by Santos et al., results indicated that nano-
topography of CaP samples strongly affected the protein adsorption process 
[127]. As such, a rough will increase the adsorption of fibronectin, which then 
leads to greater hfMSC attachment over the smooth, polymeric microcarriers. 
This has been confirmed in this study. From the FDA/PI and PrestoBlue 
results, proliferation and viability of hfMSCs seeded on apatite microcarriers 
were assessed. Through CLSM, hfMSCs appeared to be largely viable 
throughout the culture days, suggesting that the material composition of the 
apatite microcarriers had little or no cytotoxic effects. This was further 
confirmed through PrestoBlue results, showing that cell proliferation on 
apatite microcarriers was 1.4-fold higher than that of Cytodex 3 microcarriers, 
by day 9.  




Although adherent monolayer culture resulted in the highest proliferation of 
hfMSCs, apatite microcarriers could have yielded higher cell numbers per unit 
volume of media used. Apatite microcarriers were able to yield 3.3 x 105 
cells/ml, while conventional adherent monolayer culture flasks were only able 
to yield approximately 1.5 x 105 cells/ml. This translates to a 2.2-fold increase 
in cell yield for apatite microcarriers, compared to monolayer culture flask. In 
this regard, apatite microcarriers offers higher cell yield while requiring less 
space and cell medium.  
To evaluate if the apatite microcarriers could be used for bone regenerative 
applications, the in-vitro osteogenic potential of hfMSCs cultured on apatite 
microcarriers was investigated. ALP expression of hfMSCs culture on apatite 
microcarriers remained high after day 12, suggesting that osteogenic 
differentiation and expression were maintained, thus promoting greater 
mineralisation of ECM. Indeed, the trend in ALP expression was closely 
related to collagen I synthesis and calcium uptake. In contrast, ALP expression 
for hfMSCs cultured on the adherent monolayer culture saw a dip after day 9, 
accompanied by a levelling off for collagen I synthesis and calcium uptake. 
Apatite microcarriers without cells cultured onto them did not result in any 
significant change in the ALP, collagen I or calcium uptake, thus confirming 
that hfMSCs were the main contributors to the indicators of osteogenic 
potency. 
The information obtained from the in-vitro evaluation of apatite microcarriers 
are in agreement with studies, which have shown that hfMSCs exhibit higher 




osteogenic potency when cultured on 3D substrates that mimics the chemical 
and morphological structure of physiological bone mineral [128]. While the 
exact reason for the disparity between monolayer and microcarrier culture for 
osteogenic differentiation is unclear, it can be speculated that hfMSCs respond 
favourably to the chemical and morphological cues that the apatite 
microcarriers provide in-vitro [129].  Moreover, the adsorption of Matrix-Gla-
Protein (MGP) from the serum onto apatite acts as a precursor for osteogenesis, 
by binding and regulating the function of bone morphogenic proteins (BMPs) 
[130].  
It has been established that cell-matrix and cell-cell interactions are vital 
factors influencing cell behaviour and osteogenic potency [131]. The 
underpinning relationship between microporous structure and cell behaviour is 
not fully understood, but it is possible that the microporous architecture 
facilitates the building of cytoskeletal cell bridging networks. This was 
observed during immunoflourescent staining, where the presence of dense 
cell-cell connections within each microcarrier, and organisation of F-actin 
from the attached cell surface, would indicate that an apatite microporous 
structure was an appropriate substrate for hfMSC proliferation.  Additionally, 
the size of the microcarriers played an important role in osteogenic potency of 
hfMSCs. Fischer et al. reported that small micrometre-sized apatites of 
diameter ~260 µm exhibit greater osteogenic potency as compared to large 
micrometre-sized apatites of diameter ~600 µm [112], thus supporting results 
presented in this study. It is plausible that the packing of the particles has 
created a three-dimensional microenvironment suitable for bone formation to 




occur. This 3D environment created by the packing of the particles provides 
the macroporosity and free space required for invasion by body fluids, 
nutrients, host cells, and blood vessels. On day 9 of in-vitro culture, hfMSC-
loaded apatite microcarriers tended to form aggregates of 3 carriers or more, 
and this was accompanied by high expression of ALP, collagen I and 
osteocalcin. Whether or not aggregation was a prerequisite for or consequence 
of osteogenic potency requires further study, but the presence of aggregation 
among microcarriers would indicate good osteogenic expression in hfMSCs. 
!
4.5 Summary 
Current bone tissue engineering solutions require a large dosage of stem cells, 
and the incorporation of a scaffold that is chemically similar to natural bone, 
in providing a microenvironment that mimics the in vivo physiological 
conditions. The authors have developed apatite microcarriers to address these 
needs. In-vitro cytocompatibility study of hfMSCs cultured on the 
microcarriers shows higher cell attachment and proliferation as compared to 
Cytodex 3 microcarriers. This observation indicates that apatite microcarriers 
have the potential for greater cell yield per unit volume. In addition, in-situ 
osteogenic differentiation of hfMSCs is supported, with cells showing greater 
ALP, collagen I and osteocalcin expression than that of the adherent 
monolayer culture. Certainly, apatite microcarriers present an effective and 
scalable approach for stem cell culturing. 




Chapter 5  
In-vivo Evaluation of Subcutaneously 
Implanted Apatite Microcarriers 
5.1 Introduction 
While the in-vitro assessments of apatite microcarriers have thus far been 
favourable in proving its feasibility as a platform for MSC culture and 
osteogenic differentiation, there were still significant gaps before the efficacy 
and biocompatibility of the biomaterial could be ascertained for its application 
as an injectable, MSC-loaded microcarrier for bone tissue engineering 
applications.  
Firstly, in-vitro osteogenic potency assays were limited to studies of 
expression of specific protein markers for osteogenesis, which does not 
necessarily prove its in-vivo bone formation capacity. Furthermore, in-vitro 
studies involving just MSCs did not take into account the various cell types 
that are involved with in-vivo osteogenesis, and their associated biomolecular 
processes. As mentioned in Section 2.1, bone healing and formation is a 
complex biological process involving both extrinsic and intrinsic biological 
factors orchestrated in a specific sequence. The in-vitro study could not truly 
replicate the in-vivo diversity of cell types and provide the physical, 
mechanical and biological microenvironment that simulates the conditions at 
the defect site. Finally, in-vitro studies of the apatite microcarriers were 
limited to studies of cytocompatibility, which were not a true reflection of the 
biocompatibility of the biomaterial. The host-tissue interaction following 




implantation has to be conducted in an in-vivo environment so as to assess the 
host’s immune response to the biomaterial. While certain indicators of 
undesirable cell response or release of harmful products can be obtained from 
studies of in-vitro cytotoxicity, several other responses such as macrophage 
activity, cytokine release and formation of granulation tissue cannot be 
replicated in an in-vitro setting. Moreover, long-term biocompatibility issues 
such as tissue necrosis and fibrous tissue encapsulation cannot be anticipated 
by in-vitro studies.  
For these reasons, it is necessary to conduct in-vivo studies to assess the 
apatite microcarrier’s capacity for bone regeneration, the host tissue response 
to MSCs, as well as overall biocompatibility. Several in-vivo models have 
been established in assessing osteogenic potency and biocompatibility. Small 
animal studies such as mice, rats, and guinea pigs represent the very first step 
towards predicting clinical performance of biomaterials. The advantages of 
using these animals are their ease of availability, low husbandry requirements 
and low costs associated with holding the animals. In bone tissue engineering 
applications, their high bone turnover rates also make it particularly attractive 
by allowing for faster product development cycles. Medium (e.g. rabbits) and 
large animal (e.g. cows, sheep) represent an incremental approach towards 
obtaining relevant pre-clinical information, which would accurately predict its 
performance in the patient. These animals provide better representation of the 
human physiological processes, and would allow for more surgically 
appropriate techniques to be implemented so as to assess the biomaterial’s 
ease of application.  




In summary, in-vivo studies are indispensible in biomaterial development. 
Individually, no one animal model can simulate an exact representation of the 
human system, but together, they bridge the gap in determining clinical 
performance of the product. For the purposes of this report, focus will be on 
the small animal in-vivo assessment of the apatite microcarriers, although 
medium animal and large animal studies should be considered in its 
subsequent development. 
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5.2 Materials and methods 
5.2.1 Samples, animals and ethics 
Foetal tissue collection was approved by the Domain Specific Review Board 
of National University Hospital (DSRB-D-06-154), Singapore in compliance 
with international guidelines regarding the use of foetal tissue for 
research[132]. Pregnant women gave separate written consent for the clinical 
procedure and for the use of foetal tissue for research purposes. And foetal 
tissues were collected from foetuses after clinically indicated termination of 
pregnancy. Foetal gestational age was determined by crown-rump length 
measurement. Two foetal samples at 10+6 and 14+2 (weeks + days) gestations 
were utilized for this study. 
Six to eight weeks old immunodeficient female NOD/SCID mice were 
acquired through Jackson Labs, and all procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) at National University 
of Singapore. All materials used were purchased from Sigma–Aldrich 
(Singapore) unless otherwise stated. 




5.2.2 Isolation and characterisation of hfMSCs 
hfMSC was isolated through plastic adherence, and culture expansion, and 
characterized through immunophenotyping, colony-forming capacity and tri-
lineage differentiation into osteoblasts, adipocytes and chondrocytes as 
previously described. Brieﬂy, single-cell suspensions of foetal bone marrow 
were prepared by ﬂushing the marrow cells out of humeri and femurs using a 
22-gauge needle into Dulbecco’s modiﬁed Eagle’s medium (DMEM, Sigma, 
USA) eGlutaMAX (GIBCO, USA) supplemented with 10% foetal bovine 
serum (FBS), 50 U/ml penicillin, and 50 mg/ml streptomycin (GIBCO, USA) 
(referred as D10 medium), and then plated onto T-175 flasks at 106 
mononuclear cells/ml in D10 medium. Media was changed every 2-3 days and 
non-adherent cells were removed, and sub-cultured at 103/cm2 to sub-
conﬂuence (Day 1 to day 7). hfMSCs at passage 3 were used in this study. 
5.2.3 Microcarrier Culture 
20 mg of apatite microcarriers were weighed and washed with PBS (Mg2+, 
Ca2+ free) two times. They were then sterilised by autoclaving at 121°C for 20 
minutes. Before use, the microcarriers were soaked in 12 ml D10 medium 2 
hours at 37°C. For microcarrier culture, non-adherent 6-well plates were used. 
The carriers were then separated to 6 wells containing 2 ml of apatite 
microcarriers each. Cells were seeded with a density of 5 x105 cells per 
well.  The initial seeding regime consists of an agitation phase using a rocker 
device for 5 minutes, followed by a rest phase of 25 minutes.  This process 
was conducted for another 3 hours, after which the well plate was placed in an 
incubator at 37°C, 5% CO2 and 95% humidity. 




In-vitro culture of the cell-loaded microcarriers is conducted in two phases: 
expansion and pre-differentiation. In the expansion phase (Day 7 to 14), cells 
were cultured in D10 medium, and medium changed every 2 – 3 days. Cell 
medium was then changed to bone induction medium (D10 supplemented with 
10mM β-glycerophosphate, 10 nM dexamethasone and 0.2 mM ascorbic acid) 
and cultured for another 14 days (Day 14 to 28) with medium changed every 2 
– 3 days (Figure 5.1).  
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Figure 5.1. Experimental time line for the in-vivo study of hfMSC-loaded 
apatite microcarriers. 
Days 1 through 28 represented the pre-implantation stage, involving expansion 
and pre- differentiation phases. Day 42, month 2 and month 3 corresponded to 
the time points of 2 weeks, 1 month and 2 months post-implantation 
respectively. 
5.2.4 In-vivo implantation and ectopic bone formation 
Three groups of implants were prepared such that the study consisted of the 
following groups of implants: 
Group 1: Control groups in which dorsal pockets implanted with fibrin 
gel only   




Group 2:  Fibrin gel + apatite microcarriers  
Group 3: Fibrin gel + hfMSC-loaded apatite microcarriers 
Ectopic bone formation was examined at on day 42, month 2 and month 3 (2 
weeks, 1 month and 2 month after implantation), with a sample size of n = 5 at 
each time point, resulting in a total of 15 NOD/SCID mice used.  
Prior to the procedure implants group 2 and group 3 was created by mixing 20 
mg of apatite microcarriers (hfMSC-loaded for group 3) with 20 ul of fibrin 
solution. After thorough mixing, another 20 ul of thrombin solution is then 
added to convert the soluble fibrinogen into an insoluble mass, in accordance 
with the manufacturer’s directions (Tisseel Kit, Baxter). Group 1 was created 
in a similar manner, without the addition of the apatite microcarriers. The 
implants were kept bathed in 37 °C D10 solution until its use is required. 
Two 20 mm midline dorsal skin incisions were made (one upper and one 
lower dorsal midline) on anesthetized NOD/SCID mice. 4% isoflurane at 
2L/min was used to induce anaesthesia, while 1 – 2% isoflurane at 2L/min was 
use to maintain anaesthesia.  Subcutaneous pouches were produced using a 
sterile blunt forceps through bunt dissections. Each mouse received three 
implants (Groups 1 – 3), one on the upper dorsa area and two on opposite 
sides of the lower dorsa area. Wounds were closed with interrupted 6-O vicryl 
sutures. Mice were weighed pre and postoperatively to monitor weight 
changes, and given Caprofen as a painkiller postoperatively for three days at 
5mg/kg and Enrofloxacin as an antibiotic administered twice daily for five 
days postoperatively at 10mg/kg. At the designated time points (Figure 5.1), 




mice were euthanized using CO2, and samples were retrieved and stored for 
examination. 
5.2.5 Sample preparation 
For histological analysis, samples were fixed in 10% neutral buffered formalin 
(Sigma) for 3 – 4 hours and immersed in 10% formic acid (Sigma) for 
decalcification overnight. After dehydration in ascending concentrations of 
ethanol and xylene, they were then embedded in paraffin, cut into 5 µm 
sections and mounted on silane-coated slides. For von Kossa analysis, the 
decalcification step was excluded.  
For immunohistological analysis, samples were immersed in a 30% sucrose 
solution overnight at 4 °C for gradual dehydration, snap frozen in dry ice and 
stored at -70 °C prior to cryosectioning. Samples were then embedded in OCT 
medium (Tissue-Tek, USA), allowed to solidify at -80 °C and sectioned to 8 
µm using a cryostat (Leica CM1950, Germany). Sections were then mounted 
on poly-L-lysine slides, and fixed with 4% paraformaldehyde for 10 min. 
5.2.6 Histological analysis 
Sections were deparaffinised and rehydrated using xylene and graded 
concentrations of ethanol. They were then washed twice and immersed in 
Harris haematoxylin (Sigma) for 10 minutes before blueing by rinsing in 
Scott’s tap water (Sigma). The section was then counterstained with eosin 
(Sigma) and passed through graded series to ethanol to dehydrate the sample. 
Finally, it was cleared with xylene and mounted with DPX and closed with a 
coverslip. 




In Masson’s trichrome staining, sections were deparaffinised and rehydrated 
similar to the H&E staining step and mordant in Bouin’s solution (Sigma) at 
56 °C for 15 minutes. The slide was then rinsed in running tap water until the 
yellow colour was removed. Weigert’s iron haematoxylin (Sigma) was then 
added to the slide for 5 minutes followed by a washing in deionised water. The 
slide was then stained with Biebrich scarlet acid fuchin solution for 5 minutes 
and washed with deionised water. The slide was placed in phosphotungstic-
phosphomolybdic acid solution (Sigma) for 5 minutes before it is stained with 
aniline blue solution for 5 minutes. Finally, the slides were immersed in 1% 
acetic acid solution for 2 minutes, rinsed, dehydrated, cleared and mounted 
with a coverslip. 
All slides used for H&E and Masson’s trichrome were visualised using an 
inverted light microscope (Olympus IX83, USA) at various magnifications. 
5.2.7 Immunohistological analysis 
Slides were permeabilised with 2% Triton-X (Sigma) for 15 minutes, followed 
by a washing step with deionised water. The slides are then blocked with 5% 
bovine serum albumin for 4 hours and incubated at 4 °C overnight with either 
i) Rabbit anti- osteopontin (1:200 Abcam, USA) or ii) Rabbit anti-human 
osteonectin (1:200 Abcam, USA). Samples were then washed twice with 
deionised water and incubated with AlexFlour 594 goat anti-rabbit IgG (1:200 
Life Technologies, UK). Samples are then counterstained with 4',6-diamidino-
2-phenylindole (DAPI) (Life Technologies, USA) and mounted with coverslip. 
Stained samples were viewed under a confocal laser microscope (Olympus, 
FV300 Fluoview, Japan) at various magnifications. 





Parametric data are shown as mean ± standard deviation. Student’s t-tests were 
carried out to determine the significance between different experimental 
conditions (a p<0.05 is considered as significant). 
5.3 Results 
5.3.1 Haematoxylin and eosin study 
A haematoxylin and eosin (H&E) staining was conducted to examine general 
tissue morphology of the implanted groups (Figure 5.2). 
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Figure 5.2. Haematoxylin and eosin staining of subcutaneously implanted 
apatite microcarriers. Group 1 (Fibrin only), Group 2 (Apatite microcarriers + 
fibrin) and Group 3 (hfMSC loaded apatite microcarriers + fibrin) 
 




By comparing tissue morphology of the H&E stained sample groups across 
the period of the study, it could be observed that both apatite microcarriers 
only and hfMSC loaded apatite microcarriers exhibited continuous tissue 
formation across the period. During the first 2 weeks of implantation, fibrin 
was resorbed into the body of the mouse as evidenced by the general sparsing 
out of tissue seen at 2 weeks. From day 30 to month 2, tissue formation 
increased as seen from the figures showing denser tissue organisation. By the 
second month, the surrounding tissue was tightly associated with the apatite 
microcarriers indicating good bioactivity between the apatite microcarrier and 
the surrounding cells, and absence of fibrous tissue encapsulation. In group 1, 
implants with fibrin gel only resulted in loosely dispersed tissue morphology 
on week 2. By day 30, all the fibrin had been resorbed by the body and can no 
longer be retrieved for examination. 
!
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Figure 5.3. High magnification H&E of (a) apatite microcarriers + fibrin 
and (b) hfMSC loaded apatite microcarriers + fibrin at 2 months of 
implantation. Circle (dotted) indicates capillary formation while arrow 
indicates osteoclast bone remodelling. 
 




Comparing between groups 2 and 3, tissue formation around hfMSC loaded 
apatite microcarriers appeared to be denser and better organised as compared 
to those of apatite microcarriers only. At higher magnification (Fig. 5.3), cells 
attached to the microcarriers in (Figure 5.3b) seem more flattened and 
elongated, suggesting that these cells were osteoblasts. There was also 
presence of multi-nuclei units (arrows), which indicated possible osteoclasts, 
thus suggesting that bone remodelling was occurring within groups containing 
hfMSC loaded apatite microcarriers. In both groups, microcapillaries could be 
seen interspaced between the microcarriers. Neo-vascularisation within the 
implants would be beneficial towards the supply of nutrients and removal of 
waste to and from the cells growing on and around the apatite microcarriers. 
5.3.2 Masson’s trichrome study 
To differentiate between the types of tissue formed, a Masson’s trichrome 
histology staining was also done (Fig. 5.4). 
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Figure 5.4. Masson’s trichrome staining of group 2 (apatite microcarriers + 
fibrin) and group 3 (hfMSC-loaded apatite microcarriers+ fibrin) 




Comparing tissue formation across the days, it was evident that the tissue type 
formed by group 3 was different from group 2; in addition to the denser tissue 
formation, hfMSC loaded apatite microcarriers exhibited greater production of 
connective tissue (blue colouration). The blue colouration observed was 
mainly due to staining of collagen I fibres, regarded as the main organic 
constituent of bone. Connective tissue organisation of group 3 at 2 months 
also resembled that of native woven bone formation. 
5.3.3 Von Kossa study 
Von Kossa staining of the implanted apatite microcarriers to observe for 
presence of tissue mineralisation (Figure 5.5). This stain results in dark, 
opaque spots when calcium deposits are encountered, and required samples to 
be prepared without a decalcification step. 
 
Figure 5.5. Von Kossa staining of implanted apatite microcarriers alone 
(group 2) and hfMSC-loaded (group 3). Black spots indicate heavy 
mineralisation.  
!




For group 2, insufficient dense tissue around the microcarriers at month 2 
resulted in disintegration of the sampled sections, and as a result, von Kossa 
staining cannot be obtained. While it was expected for apatite microcarriers to 
be stained heavily, calcium deposits could be observed in the intergranular 
space of both groups as early as week 2. By 2 months after implantation, 
apatite microcarriers appeared more porous, with higher mineralisation 
observed between the granules.  
5.3.4 Osteopontin and osteonectin expression 
To identify the contribution of osseous tissue by hfMSCs, samples were 
cryosectioned and stained for human specific osteopontin. Osteopontin (OP), 
also known as bone sialoprotein I (BSP-1) is synthesised predominantly by 
osteoblasts and osteoclast, and is involved with tissue mineralisation as well as 
bone remodelling. The tissue samples were also counterstained with DAPI and 
viewed under a confocal laser-scanning microscope.  
From figure 5.6, it could be observed that the hfMSC loaded apatite 
microcarriers expressed osteopontin, while low levels of expression was 
observed with the apatite microcarriers alone. This indicated that the hfMSCs 
remained viable throughout the study, and they were actively contributing to 
osteogenesis.  





Figure 5.6. Immunohistology of group 2 (apatite microcarriers + fibrin) 
and group 3 (hfMSC loaded apatite microcarriers + fibrin) tissue samples. 
Slides were stained for human specific osteopontin (red) and counterstained 
with DAPI (blue). 
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Figure 5.7. Osteopontin coverage normalised to cell nuclei count (n = 5) at 
various time points. hfMSC-loaded apatite microcarriers express 2.7-fold 
greater osteopontin compared to the group containing apatite microcarriers 
only(*p < 0.05, **p < 0.001). 
!




The expression of osteopontin relative to the number of cells present was then 
quantified to further demonstrate the contribution of hfMSCs to osteogenesis. 
As can be seen from figure 5.7, groups containing just apatite microcarriers 
alone resulted in approximately 1.9 fold increase in osteopontin expression 
after 2 months of study. In contrast, hfMSC-loaded microcarriers exhibited an 
increasing trend in osteopontin expression, with a 4.8 fold increase after 2 
months. Comparing between apatite microcarriers only and hfMSC-loaded 
apatite microcarriers, there was a 2.7 fold greater osteopontin expression after 
2 months post implantation. 
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Figure 5.8. Immunohistology of human specific osteonectin (red) on (a) 
apatite microcarriers only (Group 2) and (b) hfMSC-loaded apatite 
microcarriers (Group 3), 1 month post-implantation. Samples were 
counterstained with DAPI (blue).  
 
Osteonectin (ON), also known as secreted protein acidic and rich in cysteine 
(SPARC) is an acidic ECM secreted predominantly by mature osteoblasts. ON 
displays affinity for type I collagen and calcium, and has been implicated in 
playing a major role in bone formation, initiating mineralisation and 




promoting mineral crystal formation. Immunohistological staining of human 
specific ON in group 2 and 3 at day 30 demonstrated high expressions of ON 
with the hfMSC-loaded group, but negative with the apatite microcarriers only 
group (Figure 5.8). This suggested that hfMSCs that are proliferating and 
differentiating on the apatite microcarriers remain viable after implantation, 
and that the osteogenic phenotype was maintained.   
5.4 Discussion 
In this study, the in-vivo osteogenic potency of hfMSCs when cultured on 
apatite microcarriers was demonstrated. Osteogenic differentiation of the 
hfMSC loaded apatite microcarriers during the in-vitro cell culture phase prior 
to implantation resulted in proliferation of hfMSC, and expression of key 
osteogenic markers (ALP, COL I and osteocalcin) with evidence of ECM 
production (Section 4.3). These factors would contribute to the in-vivo 
formation of new bone tissue. With respect to the in-vivo results, by 
comparing between empty apatite microcarriers (group 2) and hfMSC-loaded 
apatite microcarriers (group 3), an increase in tissue density, organisation, and 
mineralisation can be observed. Various cell morphologies resembling that of 
osteoblasts and osteoclasts could be observed on the surface of the hfMSC-
loaded apatite microcarriers, with presence of woven bone tissue formation 
observed at the intergranular space. These observations were consistent with 
evidence of ectopic bone formation, which were absent in groups containing 
apatite microcarriers only. Formation of ectopic bone in-vivo was the result of 
a complex process that involved several factors including i) presence of donor 




cells responsible for osteogenesis, ii) intrinsic host condition, and iii) the 
physiochemistry of the biomaterial. 
The incorporation of donor cells in the stimulation of osteogenesis is a known 
factor in the paradigm of bone tissue engineering, with MSCs being the most 
commonly used cell type in such an application. MSCs are found in all stages 
of life, and can be obtained from perinatal and postnatal sources including 
adipose tissue, bone marrow and umbilical cord blood [133-135]. These cells 
have been reported to result in-vivo osteogenicity, both in ectopic bone 
formation models and orthopaedic bone defect models. Human foetal MSCs 
were chosen because they have been reported to possess superior osteogenicity 
and reduced immunogenicity[136-138]. When cultured with the apatite 
microcarriers, they demonstrated enhanced osteogenic potency over those 
cultured on conventional monolayer tissue culture flasks. This presented 
advantages of reducing time and resources required for high throughput 
applications and treatments requiring large doses of MSCs, while ensuring 
high phenotypic fidelity. The culture of MSCs on the apatite microcarriers also 
presented a highly attractive platform as an injectable bone graft substitute 
with osteoconductive and osteogenic properties that have the potential for 
enhanced bone healing rates and reduced recovery time. The role of donor 
MSCs in induced osteogenesis had not yet been fully established, although 
several mechanisms have been proposed. These included i) direct provision of 
an osteogenic cell source capable of self-renewal and bone formation[139-
141], ii) expression and regulation of osteogenic factors which influence and 
modulate the migration and differentiation of the host’s osteoprogenitors[142, 




143] and iii) creation of a hyperbaric microenvironment conducive for de novo 
bone formation through the enhancement of implant neovascularisation[144-
147].  
The information obtained this in-vivo study of hfMSC-loaded apatite 
microcarriers suggested a strong relationship between presence of hfMSC and 
new bone formation in an ectopic mouse model. It was possible that a 
combination of the aforementioned mechanisms were responsible for the 
presence of woven bone tissue formation. In addition to the enhanced 
expressions of type I collagen, osteocalcin and ALP as reported in the in-vitro 
study, high levels of osteopontin and osteonectin were observed in groups 
containing hfMSC-loaded apatite microcarriers. These proteins played a 
crucial role in bone formation and mineralisation, in which OP was 
responsible for the attraction and distribution of osteoblasts and its progenitors 
as well as regulating osteoclast activity[148, 149] while ON was involved with 
the mineralisation of bone[150]. Together, both OP and ON expressions 
observed were in agreement with histological studies, which revealed the 
presence of osteoblasts and osteoclasts and indications of bone mineralisation. 
This contrasted strongly against groups containing apatite microcarriers only, 
in which OP and ON expression remained low throughout the days of study, 
and new bone formation could not be clearly established.  
Accounting for the variability of the intrinsic host condition, NOD/SCID mice 
(n = 15) were used in this study. Krebsbach et al. found no obvious difference 




in host dependent parameters with respect to the strain of immunodeficient 
mouse recipients (SCID, beige or beige/SCID)[151]. 
Concerning the physicochemistry of the biomaterial, apatite microcarriers 
were similar to the mineral phase of bone in terms of chemical composition. 
Apatite possesses osteoconductive properties, which allowed for the migration 
of osteoblasts and in-growth of tissue for proper osteointegration between host 
tissue and biomaterial. Osteoconductivity and bioactivity were also dependent 
on the bulk properties of the biomaterial, its pore size (micro and marco-scale), 
porosity, interconnectivity and resorption characteristics[152, 153]. For 
example, Krebsbach et al. found more extensive bone formation with HA/TCP 
powder than in HA/TCP blocks[139]. The apatite microcarriers featured in 
this study were porous spherical particles measuring approximately 0.23 mm, 
which fell within the range reported by Makani et al., reporting that peak bone 
formation was observed with spherical particles between 0.1 – 0.25 mm[152]. 
It was possible that the apatite microcarriers had a size range necessary for 
optimal intergranular spacing, enabling the creation of macropores necessary 
for tissue in-growth and blood vessel formation[109]. A microporosity of 2 – 3 
µm was also observed with the apatite microcarriers, and this was suggested to 
be beneficial towards in-vivo bone formation, consistent with other reports 
featuring apatite scaffolds with micro scale (< 10 µm) pore size[112, 154, 155]. 
This was so because micropores of the apatite microcarriers confer a high 
surface area for protein adsorption. Furthermore, the roughness and surface 
topology resulting from micropores allowed for appropriate physical cues for 
osteoblast adhesion, proliferation and differentiation. 




It should be noted however, that intrinsically, apatite did not possess 
osteoinductive properties, which was the reason why implant groups 
containing apatite microcarriers only did not result in substantiated ectopic 
bone formation. In ectopic implant conditions, bone formation required the 
active recruitment and stimulation of MSCs, which were usually found in the 
periosteum of the bone. Subcutaneous implantation of the apatite microcarriers 
meant that the biomaterial was separated from this source by a thick layer of 
muscle and connective tissue, thus preventing any direct contact with the 
host’s MSCs. In addition, as there was little or no rupture of blood vessels 
during the implant procedure, no hematoma was created, thus disrupting the 
initial inflammation cascade; an important step towards initiating bone healing 
and regeneration. Hence, without the incorporation of hfMSCs, the ability of 
the host to initiate bone regeneration at the implant site was hindered, thus 
resulting in a less defined tissue morphology with little mineralisation. This 
was consistent with studies confirming that osteoinductive factors or 
osteogenic cells had to be incorporated in the biomaterial for any 
osteoinductive effect to be realised in a bone defect model[112, 156-159]. 
Neovascularisation is integral towards long-term success of the biomaterial, 
and plays a major role in facilitating endochondral and intramembranous 
ossification, thus determining the rate of new bone formation[160]. 
Microcapillaries could be observed with implant groups containing hfMSC 
loaded apatite microcarriers. This was in agreement with reports proposing the 
use of MSCs for the treatment of tissue ischemia and myocardial deficiencies, 
due to their angiogenic effects[161, 162]. It had been reported that MSCs 




express a range of blood vessel inductive factors such as angio-associated 
migratory cell protein (ANG) 1 and 2, endothelial growth factor (EGF) 1, and 
vascular endothelial growth factor (VEGF)[163]. This had been confirmed by 
Kinnaird et al., in which proliferation and migration of endothelial cells were 
promoted with the addition of MSCs in a dose-dependent manner, reducing 
muscle atrophy in a murine hind limb ischemia model [164]. In addition, the 
macrostructural properties of the apatite microcarriers had an important 
function of creating macropores, which was crucial towards facilitating 
vascularisation and angiogenesis. For granular particles, macropores were 
created as a result of intergranular spacing, governed by particle packing 
principles. In general, spherical particles resulted in the greatest void spaces 
being created between the particles. In bone tissue engineering, macropores of 
around 300 µm have been recommended for the formation of capillaries[112]. 
The apatite microcarrier’s size and shape made it possible to fulfil this 
requirement. Indeed, intergranular space (macropores) of approximately 200 
µm had been observed with implanted apatite microcarriers, and this was 
accompanied by presence of microcapillaries (Figure 5.3a).  
5.5 Summary 
The subcutaneous implantation of hfMSC-loaded apatite microcarriers in a 
mouse model was described. Over a 2-month long implantation period, 
implant groups containing hfMSC-loaded apatite microcarriers exhibited a 
dense of tissue organisation, with evidence of tissue mineralisation. 
Histological staining of decalcified sections also reveal presence of osteoblast 
and osteoclast-like cell morphologies, indicating that the processes of 




osteogenesis and bone remodelling are occurring. These indications suggested 
the formation of ectopic new bone. In contrast, samples obtained from implant 
groups containing apatite microcarriers alone resulted in loosely organised 
fibrous tissue, with little evidence of mineralisation. Cells also resembled a 
more fibroblastic morphology, which do not indicate presence of new bone 
formation. These findings suggested that ectopic bone formation could be 
predominantly attributed to the presence of hfMSCs cultured on the apatite 
microcarriers. These was further confirmed through immunohistological 
staining, in which OC and ON were highly expressed in implant groups 
containing hfMSC-loaded apatite microcarriers.  
Overall, it had been demonstrated that hfMSCs that were cultured on the 
apatite microcarriers remained highly viable during the expansion and 
differentiation phase, which occurred in-vitro. When implanted 
subcutaneously, these cells secreted factors responsible for osteogenesis and 
mineralisation of the implant, thus supporting ectopic new bone formation. 
Moreover, the apatite microcarriers exhibited little to no cytotoxic effects 
when implanted subcutaneously in the mice, thus suggesting that the 
microcarriers would not elicit an adverse host immunologic response. Lastly, 
neo-vascularisation was permitted, as evidenced by the presence of 
microcapillaries in both implant groups. This was possible because the apatite 
microcarriers fell between the recommended size range necessary for bone 
tissue formation and vascular invasion, whilst possessing favourable 
roughness, microporosity and physicochemical properties that would promote 
the conduction of osseous tissue over its surface.  




Chapter 6  
Conclusions 
The fabrication, characterisation, in-vitro and in-vivo evaluations of porous, 
apatite microcarriers for bone tissue engineering applications has been 
presented. The development and optimisation of such microcarriers have been 
performed, and this process allows for various parameters to be experimented 
with, and with careful manipulation of these factors, it is possible to fabricate 
phase-pure apatite microcarriers of appropriate size and spherical 
macromorphology. Moreover, micro-scale features can be engineered on the 
microbeads such that it adequately recreates the in-vivo micro-architecture of 
the native bone. This includes the control of the microcarriers’ chemical 
composition and crystallinity, surface roughness, pore size and overall 
porosity, which are all crucial factors that influence stem cell behaviour and 
long-term viability.  In addition, the chemical properties of apatite, as 
confirmed through chemical characterisations, will enable the microcarriers to 
have a chemistry similar to the mineral phase of native bone, and adsorb 
proteins, which will enable appropriate cell responses.  
This novel biomaterial is intended as a bone tissue engineered bone graft 
substitute, incorporating properties of excellent biocompatibility, 
osteoconductivity, and when cultured together with appropriate cell types, can 
result in new bone formation. These properties have been established through 
in-vitro and in-vivo studies. In-vitro culture of MSCs with the apatite 
microcarriers resulted in significantly better proliferation and viability over 




polymeric microcarriers. Culturing of these cells on a three-dimensional, 
apatite substrate also elicited greater osteogenic potency over cells cultured via 
conventional monolayer culture, and this is believed to be attributed to the 
microcarrier’s high surface roughness and presence of micropores, as well as 
phase pure apatite which mimics the cell’s native microenvironment, thus 
delivering the appropriate biomolecular cues which facilitates and enhances 
osteogenic expression among the cells. In summary, in-vitro studies have 
successfully established that the apatite microcarriers are an effective platform 
for obtaining MSCs with high yield and osteogenic potency. 
In-vivo studies of subcutaneously implanted MSC-loaded apatite microcarriers 
demonstrate ectopic new bone formation and evidence of neo-vascularisation. 
This is believed to be primarily attributed to the presence of highly viable and 
osteogenic donor MSCs, which were able to produce ECM and express factors 
that actively recruit host cells, thus contributing towards bone tissue formation, 
mineralisation and vascularisation. As such, this study has successfully 
validated the efficacy of using MSC-loaded apatite microcarriers to actively 
initiate, promote and facilitate new bone formation in-vivo. 
To conclude, the objectives set out initially in this dissertation have been met. 
Furthermore, the information presented in this report thus far indicates that the 
use of apatite microcarriers in a single-step, non-invasive, injectable strategy 
for healing bone defects is highly promising. It is envisioned that such a 
biomaterial will have a significant impact in the orthopaedic field, thereby 
bringing the goal of bone regenerative therapy closer to clinical fruition.






7.1 Use of  substituted apatite in the fabrication of 
microcarriers 
Apatite has the potential to undergo chemical substitutions with different 
elements and chemical groups to produce a material with altered biological 
effects. For instance, Lim et al. has featured the synthesis of silver/silicon-
cosubtituted apatite which incorporates enhanced bioactivity and antimicrobial 
properties[165]. The use of such a material in the fabrication of the 
microcarriers presents exciting opportunities for the use in clinical 
applications in which patients with severely diminished bone regenerative 
capacities are observed (i.e. Osteoporosis), or in cases of open wound trauma 
where risk of infection is of paramount concern. 
7.2 Use of apatite microcarriers in dynamic bioreactors 
The use of the apatite microcarriers as viable and efficient platform for stem 
cell expansion and osteogenic differentiation can be further explored in studies 
involving bioreactors. These bioreactors provide the dynamic conditions that 
optimise nutrient and waste exchange through fluid flow kinetics. In addition, 
shear forces created during fluid flow would impart mechanical stimuli on the 
attached cells, which has been suggested to further increase osteogenic 
potency via the mechanism of mechanotransduction[166]. This represents 
opportunities to further develop the microcarriers to incorporate properties that 
are relevant towards dynamic cell culture, as well as to investigate differences 




between cell-material and cell-medium interactions so as to gain a deeper 
understanding of cell signalling pathways.  
7.3 In-vivo evaluation of the healing of bone defects in 
medium to large sized animal models 
Further in-vivo studies involving MSC-loaded apatite microcarriers implanted 
into bone defects in medium to large sized animals are proposed. This would 
simulate a more accurate environment in which the apatite microcarriers 
would be used. By implanting these microcarriers into larger sized animals, 
information that is more representative can be obtained with regard to the 
actual implantation procedure, as well as host immunological responses to the 
presence of the apatite microcarriers. In addition, creation of a bone defect at a 
weight bearing section of the bone (i.e. femur) would better recreate the in-
vivo biomechanics that the apatite microcarriers would be exposed to, 
allowing for assessment of implant stability under loading, and subjecting the 
seeded cells with the appropriate biomechanical stimuli, which lead result in 
greater bone formation, and maturation of new bone. Finally, the process of 
defect site creation would result in the rupturing of blood vessels, allowing for 
hematoma formation, which is of great relevance towards simulating actual 
clinical conditions involving complex fractures or bone resection procedures. 
It would be interesting to investigate the performance of these apatite 
microcarriers under a more biologically and physiologically complex 
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